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Abstract 
The Role of Interleukin-10 Family Members in Inflammatory Skin Diseases 
 
Adewonuola Adelodi ALASE 
 
Keywords: Interferon lambda, Interleukin-22, Interferon stimulated genes, 
keratinocytes, fibroblasts, Inflammation, SOCS, MAPKs 
 
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that 
resolves with or without permanent scars depending on the subtype. 
Interferons (IFNs), including the skin specific IFNλ mainly activate STAT1, 
which results in inflammation in CLE and may play a significant role in scar 
formation in chronic discoid CLE. IL-22 activates STAT3 and it is emerging 
as a mediator with significant impact on normal wound repair, epidermal 
hyperproliferation and prevention of fibrosis.  
This work focussed on understanding the regulation and functional impact of 
IL-22 and IFNλ on skin cells. The counter-regulatory effect of IL-22 on the 
activities of IFNλ was assessed through downstream interferon stimulated 
genes (ISGs) expression in healthy and CLE keratinocytes. Cell proliferation 
and gap closure were investigated in skin resident cells using cell trace dye 
and scratch assay. Dermal fibroblasts were assessed for the presence of 
IFNλR1 and IL-22R1, downstream activities of the receptors. 
 Results showed that IL-22 accelerated “scratch” closure in keratinocytes 
while IFNλ caused a delay in closure. IL-22 significantly downregulated IFNλ-
induced chemokines expression in healthy, but not CLE keratinocytes. 
Reduced IL-22R1 expression and “STAT3 signature genes” was observed in 
ii 
 
CLE keratinocytes. A key finding of this project is that dermal fibroblasts 
respond to both IFNλ and IL-22.  
This work shows that IL-22 can reduce the damaging effect of IFNs in 
inflamed skin and also identifies dermal fibroblasts as important cells in skin 
immune responses. In conclusion, IL-10 family members can have both 
beneficial and destructive effects on the skin organ depending on the micro 
milieu and cell-type involved. Manipulating the balance of IL-10 family 
members in the skin may offer new therapeutic approach for both psoriasis 
and CLE. 
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1 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Inflammation-associated cutaneous scarring is an 
important health concern, which is surprisingly 
neglected worldwide. Inflammatory skin diseases, 
such as cutaneous lupus erythematosus (CLE) can 
result in scarring or non-scarring outcome even in the 
same patient. 
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1.1 The Human Skin 
The skin is one of the largest organs in the body, with a surface area of 180 
cm2, making up 16% of body weight. The skin is structured in a way which 
makes it function effectively as a physical barrier by regulating inward and 
outward flow of water and electrolytes, while also providing protection against 
entry of microorganisms, toxic agents, ultraviolet radiation and mechanical 
insults (Bos and Kapsenberg, 1986). The skin is a dynamic organ with the 
outer layer constantly shed and being replaced by the basal keratinocytes, 
which move up to the outer surface. The human skin is typically divided into 
three major layers (Figure 1.1): 
 Epidermis 
 Dermis and, 
 Subcutis or hypodermis 
        
           
        Figure 1.1:  Structure of the human skin (McGrath, 2008)  
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The epidermis is the outermost layer of the skin. It is composed of a stratified, 
keratinised epithelium, and contributes to the physical, chemical and 
immunological barrier functions of the skin. The basement membrane, which 
links the epidermis with the dermis, is a multilayered structure, which forms 
the dermo-epidermal junction. The dermal compartment provides structural 
support to the skin. It is the region of supportive connective tissue found 
between the epidermis and the subcutis or hypodermis, a layer of fat deposit 
and loose connective tissue (Wolff, 2008). Table 1.1 shows the functions of 
different layers of the skin.                                         
                            
Table 1.1: Functions of the skin 
 
 
 
 
Function Layer responsible 
Acts as sensory organ Epidermis, dermis and hypodermis 
Protects against UV irradiation Epidermis 
Temperature regulation Epidermis, dermis and hypodermis 
Fights against microbial invasion Epidermis, dermis 
Permeability barrier (prevents loss of 
moisture) 
Epidermis 
Actively participates in immunological 
surveillance 
Epidermis 
Regeneration and wound repair Epidermis, dermis 
Physical appearance Epidermis, dermis and hypodermis 
Skin firmness and extracellular 
matrix synthesis 
Mainly dermis 
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1.1.1 The Epidermis 
The epidermis is a stratified epithelium varying in thickness from around 0.4 
mm on the eyelid to around 0.8-1.5 mm on the palms of the hand and soles 
of the feet (Bensouilah, 2007; Wolff, 2008). The epidermis is without blood 
vessels and is largely composed of keratinocytes, which make up about 90% 
to 95% of the cell population. The other cell populations present in the 
epidermis are: Melanocytes, which donate pigment to keratinocytes, dendritic 
antigen-presenting cell population, termed Langerhans cells (LCs), which 
have immunological roles and Merkel cells, which are slow-adapting type I 
mechanoreceptors resident in areas of high tactile sensitivity (McGrath, 2008; 
Wolff, 2008). The epidermis is organised into four layers depending on 
proliferative ability and the maturity of keratin expressed by the keratinocytes. 
These layers are: (1) the Stratum basale above the basement membrane, (2) 
Stratum spinosum, (3) Stratum granulosum, and the outermost (4) Stratum 
corneum. Of note, the Stratum granulosum expresses molecules, such as 
antimicrobial peptides (AMP), including cathelicidin (CAMP/LL-37), B-
defensins, lipocalin 2, psoriasin (S100A7), calgranulin A (S100A8) and 
calgranulin B (S100A9), which are involved in innate immunity ((Morizane 
and Gallo, 2012; Sorensen et al., 2003). The cells in the Stratum corneum 
are referred to as corneocytes; they have lost their nuclei but have a cross-
linked protein membrane structure called cornified envelope, containing 
many layers of neutral lipids (Lowes et al., 2014).  
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1.1.2 The Dermis 
The dermis is made up of fibrous, filamentous and cellular connective tissue 
elements that accommodate vascular and nerve networks. The dermis 
provides elasticity and tensile strength to the skin, with thickness ranging 
from 0.6 to 3 mm. It functions in protecting the body against mechanical 
injury and helps in thermal regulation (Bensouilah, 2007). The dermis 
consists of many resident cells, such as fibroblasts, endothelial cells, 
macrophages, mast cell and probably some tissue resident conventional and 
non-conventional T cells, as well as transient circulating cells of the immune 
system (Glennie et al., 2015; Wolff, 2008; Zhou et al., 2015). Skin 
appendages, including sweat glands, hair follicles and sebaceous glands are 
also located in the dermis.  
 
1.1.3 Collagen 
Collagens are a family of closely related, but genetically distinct proteins 
made up of specific amino acids, such as glycine, proline, hydroxyproline and 
arginine (van der Rest and Garrone, 1991; Vuorio and de Crombrugghe, 
1990). Collagen is the major component of the connective tissue and it is the 
most abundant protein in mammals, constituting 25 to 35% of total body 
protein content (Szoka et al., 2015). Collagens are the main components of 
the ECM in the skin, synthesised predominantly by fibroblasts, with types I 
and III as the major subtypes expressed by these cells (Olsen et al., 1989). 
The amount of collagen deposited by fibroblasts is regulated by the rate of 
collagen biosynthesis and collagen catabolism (Chen and Raghunath, 2009). 
It was initially thought that all types of collagen were secreted by fibroblasts 
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alone; however, it is now well known that numerous epithelial cells make 
certain types of collagen (Lodish H, 2000). Type I collagen is the most 
abundant type in the dermis and it is responsible for skin tensile strength. On 
the other hand, type IV collagen is highly cross-linked and forms a network; 
hence, it maintains the mechanical stability of the basement membrane. 
Reduced expression of this collagen through the activity of MMP2 has been 
linked with wrinkles development (Contet-Audonneau et al., 1999). Mutation 
in the COL3A1 gene has been linked with atrophic skin, spontaneous visceral 
rupture and easy bruising (Sharma et al., 2009). In addition, collagen III 
suppression increased myofibroblasts differentiation and scar disposition in 
cutaneous wound healing (Al-Qattan et al., 2015; Volk et al., 2011). Type VII 
collagen, expressed by both keratinocytes and dermal fibroblasts is the main 
component of the anchoring fibrils, the attachment structures present in the 
basement membrane of the skin and the mucous membranes (Chen et al., 
1994). The anchoring fibrils are important for the stability of the cutaneous 
basement membrane zone. Therefore, structural abnormality or lack of the 
anchoring fibrils results in cutaneous fragility and sub-basal lamina blister 
formation as observed in dystrophic form of epidermolysis bullosa (EB) (Uitto 
and Christiano, 1992).   
 
1.1.4 Wound healing and Scarring 
Tissue injury results in the activation and signalling of cytokines and growth 
factors, involving, endothelial, epithelial, mesenchymal and immune cells in 
order to initiate wound repair. Wound repair or healing is a stepwise process 
characterised by cell proliferation, inflammation, remodelling of extracellular 
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matrix, cell invasion and migration, formation of new blood vessels and 
regulation of blood coagulation (Dauer et al., 2005). Signal transducer and 
activator of transcription (STAT) 3, a transcription factor, has been implicated 
in wound healing due to its role as a key molecule linking many signalling 
pathways involved in wound healing such as EGFR, IL-6, IL-22 and 
hepatocyte-growth factor (HGF) signalling (Li et al., 2003). Fibrosis (scarring) 
occurs as a result of epithelial injury, activation and formation of subepithelial 
myofibroblasts foci and excessive deposition of extracellular matrix. It is an 
unwanted outcome of wound healing. A major difference identified between 
normal wound healing and healing with abnormal scar formation is the 
amount of collagen deposition and the arrangement of collagen. Whereas 
there is reduced collagen deposition and a 'basket weave’ collagen 
arrangement during normal wound healing, increased collagen deposition is 
prominent in abnormal scar-forming wound healing process and the collagen 
has abnormal parallel arrangement (Occleston et al., 2010). Abnormal 
organisation of type I collagen-rich ECM during remodelling phase of wound 
healing is the hallmark of scar formation (Mah et al., 2014). Normal scar 
formation during wound healing is also characterised by increased protease 
activity and reduced amount and activity of protease inhibitors. On the 
contrary, wound repair with abnormal scar formation is characterised by 
decreased protease activity and increased presence and activity of protease 
inhibitors (Occleston et al., 2010). The process in which epithelial cells 
undergo phenotypic changes resulting in their loss of epithelial characteristics, 
and acquisition of mesenchymal phenotype referred to as epithelial to 
mesenchymal transition (EMT) has been implicated in the development of 
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fibrotic tissue (Liang et al., 2013). Fibrosis presents with high number of 
trans-differentiated fibroblasts referred to as myofibroblasts. Myofibroblasts 
are identified by overexpression of α-smooth muscle actin (α-SMA) which 
has been linked with aberrant synthesis of matrix in pulmonary fibrosis 
(Scotton and Chambers, 2007). Fibroblasts phenotype and the depth of 
wound have been identified as important factors in scar formation (Cuevas et 
al., 2007; Glim et al., 2013). During scar formation, adnexal structures such 
as hair follicles, normally present in the dermis are destroyed. Transforming 
growth factor (TGF)- β1 has been identified as a key molecule in the 
development of fibrous tissue due to its ability to attract fibroblasts, stimulate 
their proliferation and by inducing EMT either through Smad or non-Smad 
signalling (Xu et al., 2009). Scarring as a consequence of an inflammatory 
disease mostly occurs in hair follicle rich body areas and involves the 
pilosebaceous unit. The hair follicle harbours an important stem cell 
compartment and presents an immunoprivileged site. Mechanisms of 
atrophic scarring, frequent in acne and chronic discoid LE, are poorly 
understood. With regard to organ fibrosis, it has been highlighted that 
although diverse diseases can initiate fibrosis, the biochemical and cellular 
tissue responses that lead to the final outcome are largely stereotypical.  This 
may also apply to the skin and different scarring outcome as, for example, 
seen in LE may indicate that the inflammation-to-scarring pathway has been 
arrested in different phases. Cytokines, growth factors and lipid mediators 
derived from surrounding tissue cells (keratinocytes, endothelium), infiltrating 
monocyte/ macrophages, lymphocytes, and innate lymphoid cells are 
important regulators of myofibroblast differentiation and activation. IL-10 
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family members and in particular IL-22 are key molecules in skin healing 
processes (Lim and Savan, 2014). The pro-healing but anti-fibrotic properties 
of IL-22 are beginning to be recognised. It has been suggested that 
fibroblasts from CDLE patients have reduced in vitro proliferation as 
compared to those from non-scarring subtypes of CLE following UVA 
irradiation (Nyberg et al., 2000). However, the mechanism involved in tissue 
scarring in CDLE is still not well understood. Hypertrophic scars presents 
with firm papules, nodules or plaques while atrophic scars are thin depressed 
plaques. Atrophic scar is the type mainly seen in CDLE and it is 
characterised by reduced collagen expression, epidermal atrophy, 
hemosiderin deposition in the dermis and extravasation of erythrocytes 
(Sharma et al., 2009)  
1.2 Lupus Erythematosus 
Lupus erythematosus (LE) is a complex autoimmune disease with both 
systemic and cutaneous manifestations. The systemic disease (SLE) can be 
life threatening with conditions, such as nephritis, arthritis, serositis, 
hematologic and central nervous system involvement. The skin is the main 
target organ in LE and there is cutaneous manifestation in 85 to 90% of 
patients with SLE (Wittmann, 2011). Cutaneous manifestations can present 
on their own without signs of systemic involvement. In both cases, skin 
symptoms can significantly affect the quality of life of patients (Klein et al., 
2011; Wenzel et al., 2010). The pathogenesis of LE is multifactorial and it is 
believed to be a result of concerted action of genetic, environmental and 
immunological factors (Kuhn and Bijl, 2008; Kuhn et al., 2006). Regarding 
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cutaneous flares, research findings suggest a strong involvement of UV 
irradiation as a trigger factor (Kuhn et al., 2006; Meller et al., 2005) but 
infections, drugs and trauma are also described to initiate LE symptoms 
(Wenzel et al., 2010). The immunological mediators triggered in LE mimic the 
host’s response to viral infection which results in the production of interferons 
(IFNs) (types I, II and III) and IFN stimulated genes (ISGs), such as CXCL9, 
CXCL10, myxovirus protein A (MxA), guanylate binding protein-1 (GBP-1) 
and oligoadenylate synthetase (OAS) (Arrue et al., 2007; Kim et al., 2009; 
Naschberger et al., 2010; Wenzel et al., 2005a; Wu et al., 2011; Zahn et al., 
2010). Some other proinflammatory cytokines, such as interleukin (IL)-18, 
High mobility group box (HMGB)-1, IL-1β and tumour necrosis factor alpha 
(TNFα) have also been implicated in pathogenesis of LE (Aringer and 
Smolen, 2012; Ohl and Tenbrock, 2011; Popovic et al., 2005; Wang et al., 
2008). 
 
1.2.1 Systemic Lupus Erythematosus (SLE) 
The pathogenesis of SLE is often associated with production of 
autoantibodies, formation of immune complexes and complement activation 
resulting in inflammation (Herrmann et al., 2000; Munoz et al., 2010; Ohl and 
Tenbrock, 2011). Genetic aberration in SLE has been highlighted in studies; 
however, no single gene has been identified as the most important but rather 
several genes, such as TREX1, IRF5, ITGAM, STAT4, gene coding for C1q 
and many genes on the IFN pathway were implicated in the risk of 
developing SLE (Munoz et al., 2010; Rhodes and Vyse, 2008). Defective or 
delayed clearance of apoptotic cells, which may result in secondary necrosis, 
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is discussed as the main source of autoantigens in SLE. The accumulation of 
cellular remnants may lead to a breakdown in immunological tolerance 
resulting in autoimmune inflammation (Herrmann et al., 2000). 
Autoantibodies and nucleic acids from dying cells form immune complexes, 
which amplify immune activation, such as plasmacytoid dendritic cells (pDCs) 
activation resulting in production of type I IFNs and other inflammatory 
molecules (Lovgren et al., 2004).  
 
1.2.2 Cutaneous Lupus Erythematosus (CLE) 
The morphology and distribution of skin lesion in CLE is highly diverse and 
this has led to its categorisation into three main subtypes based on clinical 
features, laboratory abnormalities, extent and duration of skin lesion and 
histological changes. They are: 
1. Chronic discoid CLE (=CDLE) 
2. Subacute CLE (= SCLE) 
3. Acute CLE (=ACLE)  
1.3 Scarring and non-scarring CLE 
CDLE mostly presents with a scarring outcome whereas skin lesions in the 
context of SCLE and ACLE heal without scarring.  
 
1.3.1 Scarring CLE 
CDLE is the most common form of CLE and it is characterised by indurated, 
erythematous plaques which may be disseminated over head, neck, trunk, 
arms and leg or localised to one area of the skin, particularly face and 
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capillitium, which is the case in about 80% of people with CDLE. The 
hallmark of this type of CLE is that it heals with significant permanent 
scarring and scarring alopecia. Transition of CDLE to SLE is rare (Kuhn et al., 
2000; Wenzel et al., 2010).  
 
1.3.2 Non-scarring CLE 
SCLE presents with annular papulosquamous erythematous plaques of 
different morphological forms. Patients suffering from this subtype of CLE are 
often highly photosensitive and show presence of anti-Ro/SSA and anti-
La/SSB autoantibodies, which belong to the group of antinuclear 
autoantibodies (ANA). Skin lesions typically heal without scarring but there 
may be post inflammatory changes in pigmentation. Histological examination 
shows features of so-called interface dermatitis, which is also seen in discoid 
CLE (Wenzel et al., 2010; Yu et al., 2013). Interface dermatitis describes 
specific morphological pattern of basal epidermal layer, characterised by 
vacuolar changes (liquefaction), high levels of keratinocytes apoptosis and 
infiltration of dermo-epithelial junction by CD8+ lymphocytes (Wenzel and 
Tuting, 2008). 
ACLE typically presents centro-facial, disseminated erythema referred to as 
malar rash or butterfly rash. ACLE is mostly found in the context of SLE. 
Patients show positive ANA and up to 90% of the patients have high anti-
dsDNA autoantibodies (Crowson and Magro, 2001).  
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1.4 Pathogenesis of CLE 
The pathogenesis of CLE remains poorly understood; however, various 
concepts have been postulated for the initial trigger and the progression of 
the disease. There is evidence for the involvement of autoantibody 
generation, ultraviolet irradiation (UV) and cytokines/chemokines 
dysregulation in the pathogenesis of CLE. Immunological, genetic and 
genome-wide studies have confirmed the important role of the IFN 
pathway/ISGs in the pathogenesis of CLE and maintenance of the chronic 
state of the disease (Dey-Rao and Sinha, 2015; Dey-Rao et al., 2014; Yu et 
al., 2013).  The clearance hypothesis, which has been suggested as the main 
trigger of CLE is briefly described below. 
 
1.4.1 UV irradiation and defective clearance in CLE 
UV irradiation is an important trigger for CLE. UV-induced keratinocyte 
apoptosis can result in the exposure of normally intracellular, nuclear 
antigens on the surface of keratinocytes (e.g. “in apoptotic blebs”), which 
may be of relevance in CLE pathogenesis (Herrmann et al., 2000; Kuhn et al., 
2006). ANA targeting these antigens are found in varying levels in CLE 
depending on the subtype, with SCLE patients having high levels of anti-
Ro/SSA and anti-La/SSB, which are associated with photosensitivity 
(Sontheimer et al., 1982; Wenzel et al., 2000a; Wenzel et al., 2000b). 
Increased apoptosis and defective clearance of apoptotic debris have been 
reported in LE patients. The defective clearance of these apoptotic cells has 
been attributed to many factors, the best described of which is deficiency in 
the complement factor, C1q (Zhang and Dong, 2007). Impaired macrophage 
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function due to the presence of autoantibodies that are specific for class A 
scavenger receptors has also been implicated in the delayed or defective 
clearance of apoptotic cells (Chen et al., 2011). Important ISGs, such as MxA, 
GBP-1, CXCL9 and CXCL10, involved in the pathogenesis of CLE have be 
shown to be highly upregulated in UV-induced cutaneous lesion, suggesting 
that UV acts as a trigger of IFN response in LE skin lesions (Naschberger et 
al., 2010). This could possibly be in the context of nucleic acids found outside 
of the cell and thus, initiating an anti-viral type immune response. Induction of 
chemokines, such as CXCL9, CXCL10 and CXCL11 in response to either 
nucleic acids or IFNs leads to recruitment of pathogenic IFNγ-producing 
CXCR3+ T cells and plasmacytoid dendritic cells (pDCs), which produce high 
amount IFNα to the skin compartment. This results in exacerbation and 
maintenance of disease state. TNFα and IL-18 are other cytokines that play 
important roles in increased keratinocytes apoptosis seen in CLE. A 
schematic for the described factors believed to be involved in CLE 
pathogenesis is shown in Figure 1.2.  
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Figure 1.2: Cytokine involvement in the pathogenesis of CLE 
CLE is characterised by interface dermatitis. Upon external trigger (UV, 
infection etc) resulting in damage and apoptosis (secondary necrosis), 
keratinocytes produce IFNλ that induces IFN stimulated proteins including 
MxA, GBP-1 and the chemokines CXCL9/10. These chemokines recruit 
IFNγ-producing CXCR3+ T cells (cytotoxic cells) and marginally pDCs. 
Chemerin as well as anaphylatoxins have been described to attract pDCs 
from peripheral blood into the dermo-epidermal junction of the skin. pDCs are 
particularly competent IFN producers. High levels of IL-18 and increased 
expression of IL-18 receptor in keratinocytes contributes to rapid apoptosis 
through increased TNFα. CLE, cutaneous lupus erythematosus; FB, 
fibroblasts; KC, keratinocytes; pDC, plasmacytoid dendritic cell; Tc, T cell; 
UV, ultraviolet light. Adapted from (Wittmann, 2011). 
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1.5 Cytokines and signalling pathways linked to CLE pathogenesis 
1.5.1 Interferon (IFN) signalling and induction of ISGs 
IFNs belong to the class 2 cytokines family and were initially known for their 
anti-viral activities. However, it is now clear that they play a major role in the 
pathogenesis of a large number of conditions, including autoimmune 
diseases, such as LE, rheumatoid arthritis (RA) and lichen planus (Vilcek, 
2006). To date, there are three types of IFNs known namely; Type I IFNs 
(IFN-α, -β, -ε, -к, -ω), type II (IFNγ), type III (IFN-λ1, IFN-λ2, IFN-λ3, IFN-λ4). 
The classification is partly due to their use of different types of receptors to 
mediate signal transduction (Table 1.2). The type III (lambda) IFNs, which 
were discovered recently by two independent groups, are also referred to as 
IL-29, IL-28A and IL-28B for the first 3 respectively (Kotenko et al., 2003; 
Sheppard et al., 2003). Type I IFNs signal through the membrane-associated 
IFNα receptor (IFNAR), consisting of IFNAR1 and IFNAR2 subunits (Lutfalla 
et al., 1995; Novick et al., 1994) while IFNγ signals through membrane-
associated IFNγ receptor (IFNγR), consisting of IFNGR1 and IFNGR2 
subunits (Soh et al., 1994). Type III IFNs (IFNλ) signal through heterodimeric 
IFN receptor complex comprising IFNλR1, selectively expressed and 
functional in certain types of cells (Kotenko et al., 2003) and the ubiquitously 
expressed IL-10R2, which is a subunit of the receptors for IL-10, IL-22 and 
IL-26 (Kotenko et al., 2003; Sheppard et al., 2003).  IFNλ is functionally 
similar to type 1 IFNs but structurally similar to the IL-10 family of cytokines 
(Miknis et al., 2010). In fact, IFNλ has only 20% homology to type I IFN; 
however, they are classified as IFN because they share intracellular 
signalling pathways (George et al., 2012). The binding of types I and III IFNs 
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to their receptors results in conformational changes which allows access to 
two member of the cytoplasmic Janus tyrosine kinases family, JAK1 and 
Tyk2. This leads to subsequent phosphorylation of members of the signal 
transducers and activator of transcription (STAT) family of transcription 
factors, mainly STAT1 and STAT2, which form heterotrimer with IFN 
regulatory factor 9 (IRF9) resulting in a heterotrimeric complex referred to as 
IFN-stimulated gene factor 3 (ISGF3). This complex translocates to the 
nucleus where it binds to IFN stimulated response element (ISRE) leading to 
activation of IFN stimulated genes (ISGs) (Li et al., 1996). The only type II 
IFN, IFNγ, binds to IFNGR (IFNGR1 and IFNGR2) resulting in access to 
JAK1 and JAK2 with subsequent phosphorylation of STAT1 homodimer 
referred to as gamma activated factor (GAF), which translocates to the 
nucleus to bind to gamma activated sequences (GAS) at the promoter region 
of downstream genes or ISGs. These IFNs induce the expression of genes, 
such as myxovirus resistant protein A (MxA), CXCL9, CXCL10, 2, 5-
Oligoadenylate synthetase (OAS), guanylate binding protein 1 (GBP-1) and 
IFN-inducible protein 16 (IFI16). The signalling pathways are described in 
Figure 1.3. 
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Figure 1.3: IFN signalling via JAK/STAT pathway  
Types I and III IFNs bind to their respective receptor complexes; resulting in 
recruitment of JAK1 and TYK2 to the intracellular compartment of these 
receptors. They activate similar downstream signalling pathways and induce 
overlapping set of genes mainly through the activation of IFN stimulated gene 
factor 3 (ISGF3) which binds to IFN stimulated response element (ISRE) at 
the promoter of these downstream genes. They can also use STAT1 
homodimer. Type II IFN (IFNγ) recruits JAK1 and JAK2, and activates STAT1 
homodimer, which binds to gamma associated sequences (GAS) to induce 
some overlapping set of genes as type I and III IFNs but also distinct set of 
IFN stimulated genes (ISGs). Adapted from (Heim, 2012) 
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Table 1.2: IFNs Classification 
Types Sub-
types 
Main 
sources 
Receptor 
Complex 
Functions Signalling 
pathways
/ 
Transcrip 
tion 
factors 
Type I 
 
IFNα (13 
isoforms 
of this 
subtype), 
IFNβ, 
IFNε, 
IFNκ, 
IFNω 
pDCs, 
fibroblasts, 
all 
nucleated 
cells  
IFNAR1 
IFNAR2 
 
Antiviral, 
antitumour, 
cytotoxicity, 
antiproliferative, 
proapoptotic  
JAK1  
TYK2 
STAT1 
STAT2 
STAT3 
STAT4 
STAT5 
NFκB 
MAPK 
 p53 
Type II IFNγ Natural 
killer (NK) 
cells, T 
cells, 
macrophag
es 
IFNGR1 
IFNGR2 
 
Antibacterial, 
antiviral, 
antitumour, Th1 
response, 
immune 
modulation 
JAK1  
JAK2 
STAT1 
STAT3 
STAT5 
Type 
III 
IFNλ1 
(IL-29), 
IFNλ2 
(IL-28A), 
IFNλ (IL-
28B), 
IFNλ4 
Keratinocyt
es, pDCs, 
hepatocyte
s 
IFNλR1 
(Mainly 
epithelial 
cells and 
hepatocyte
s) 
IL-10R2 
Antiviral, 
antitumour, 
antiviral, 
antiproliferative, 
proapoptotic 
JAK1  
TYK2 
STAT1 
STAT2 
STAT3 
STAT5 
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1.5.2 Production of IFNs 
IFNs are produced as a result of the interaction between pathogen-
associated molecular patterns (PAMPs) or damage-associated molecular 
patterns (DAMPs), such as viral or self-RNA or DNA and pattern recognition 
receptors (PRRs). Toll-like receptors (TLRs) are the best characterised of 
these PRRs. The endosomal TLRs: 3, 7,8 and 9 recognise nucleic acids. 
TLR3 recognises double stranded RNA (dsRNA), TLR7/8 recognise single 
stranded RNA (ssRNA) and TLR9 recognises unmethylated DNA with CpG 
motif (double stranded DNA, dsDNA). Another important pathway leading to 
induction of IFN is the cytosolic pathway comprising what is called the 
retinoic acid-inducible gene-I (RIG-I) like receptors (RLRs). This group 
consists of cytosolic RNA helicases, such as RIG-I and melanoma 
differentiation-associated gene 5 (MDA5) (Yoneyama et al., 2004). Activation 
of TLRs and RLRs results in signalling cascades involving nuclear factor 
kappa B (NFkB) and IFN regulatory factors, such as IRF3 and IRF7. IRF7 is 
expressed at low levels in cells but strongly activated on stimulation with type 
I IFN while IRF3 is constitutively expressed in most cells. IRF3 and NFkB act 
downstream of TLR3 and other cytosolic receptors to induce the production 
of IFNβ and IFNλ1; while TLR7/8 and TLR9 activate IRF7 and NFkB resulting 
in the production of IFNα, IFNλ2 and λ3 (Heim, 2012). Immune complexes 
containing DNA or RNA are recognized as key inducer of IFN production in 
LE conditions (Farkas et al., 2001; Zahn et al., 2011). DAMPS, such as 
cathelicidin (LL37) and high mobility group box (HMGB)-1, which are 
released as a result of assault on cells may act as adjuvant for the 
recognition of  ‘self-nucleic’ acids resulting in activation of the immune 
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system leading to proinflammatory cytokines production. LL-37, an 
antimicrobial peptide binds to and protects ‘self-nucleic’ acids from 
degradation, allowing access to TLR7 and TLR9 resulting in triggering of 
IFNα production in pDCs (Eloranta et al., 2013; Lande et al., 2007). TLR3 is 
highly upregulated in LE lesions and its ligation has been identified as a main 
trigger for type III IFN expression in human primary keratinocytes (Zahn et al., 
2010). While TLR3 agonist is extremely important in the pathogenesis of CLE, 
the endogenous source of dsRNA is still not well defined. However, a 
possible source could be long non-coding RNA (lnRNA). 
 
1.5.3 Type I IFNs 
The most extensively studied of the type I IFNs are IFNα and β. Type I IFNs 
are produced in varying amount by almost all cell types. pDCs are 
considered to be the main producers of type I IFNs and these cells have 
been shown to accumulate in skin lesions of LE patients (Farkas et al., 2001). 
The IFNAR is ubiquitously expressed; hence, most nucleated cells are 
responsive to type I IFNs (IFNα/β) (Table 1.2). IFN inducible genes (ISGs) 
also known as IFN signature genes; have been shown to be highly 
expressed in lesional skin of CLE patients. For instance, strong expression of 
MxA has been linked with local production of type I IFNs (Wenzel et al., 
2005a). CLE skin biopsies revealed that pDCs are concentrated along the 
dermo-epidermal junction and within perivascular dermal filtrates; this was 
shown to correlate with the expression levels of MxA, granzyme B as well as 
high amount of inflammatory infiltrate (Vermi et al., 2009).  The role of type I 
IFNs in enhancing Th1-biased immune response and local T-lymphocytes 
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inflammation is well documented (Klimpel et al., 1990; Wenzel et al., 2005a). 
Type I IFNs induce cytokines and chemokines, such as CXCL9/10, which 
recruit T-cells expressing the chemokine receptor, CXCR3 into the tissue. 
Ligand binding of CXCL9/10 to its corresponding receptor, CXCR3 on T-cells 
positive for the receptor has been associated with increased tissue damage 
in CLE (Amoura et al., 2003; Wenzel et al., 2005a).   
 
1.5.4 Type II IFNs 
IFNγ is the only type II IFN known and it is produced mainly by T-cells and 
natural killer (NK) cells.  IFNγ is one of the most effective molecules at 
inducing proinflammatory responses in keratinocytes (Albanesi et al., 1998). 
IFNγ-producing CXCR3+ T-lymphocytes have been implicated in the 
pathogenesis of CLE. It is believed that these cells are recruited to the 
dermo-epidermal junction by IFN inducible proteins, such as CXCL9/10 
where they produce IFNγ, thereby contributing to the IFN profile in CLE. Our 
work (Alase, 2013) suggests that the presence of IFNγ in the epidermal 
compartment of the skin may contribute to increased production of IFNλ and 
also enhance keratinocytes responsiveness to IFNλ by upregulating IFNλ 
receptor expression. Activation of keratinocytes by IFNγ also results in the 
upregulation of CD54, TLRs, MHC class I and II expression, production of 
cytokines/chemokines, such as TNFα, CXCL10, metalloproteases, such as 
MMP-1, and production of GBP-1 which has been shown to be highly 
upregulated in cutaneous lesions in CLE and is linked with reduced 
angiogenesis (Kajita et al., 2015; Naschberger et al., 2010). 
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1.5.5 Type III IFNs 
Type III IFNs were originally known to be produced by only keratinocytes and 
hepatocytes; however, our own results point to fibroblasts as an additional 
source (Alase, 2013) and pDCs have also been described to produce this 
class of IFNs. Another subset of human DCs, XCR1+ DCs, derived from 
CD34+ progenitor cells are recently reported to produce large amount of 
IFNλ (Balan et al., 2014; Tomasello et al., 2014). Whereas all nucleated cells 
are responsive to IFNα; only limited cell types, such as epithelial cells 
(keratinocytes), hepatocytes and pDCs respond to IFNλ (Dickensheets et al., 
2013; Witte et al., 2009; Yin et al., 2012). Stimulation of keratinocytes with 
IFNλ, results in the production CXCL9 and CXCL10; which are 
chemoattractant for IFNγ-producing CXCR3+ T lymphocytes (Wenzel et al., 
2005a). It has been shown that the expression of these chemokines and 
other ISGs, such as MxA correlates with the distribution of CXCR3+ T-cells in 
cutaneous lesions in CLE (Wenzel et al., 2005a; Wenzel et al., 2007). The 
overexpression of MxA is attributed mainly to the presence of pDCs in the 
skin lesion and high expression of IFNα (Wenzel et al., 2005a). However, it is 
now known that IFNλ induces MxA in keratinocytes which may contribute to 
the high expression of MxA in LE lesion (Alase, 2013).  
 
1.5.6 IFNs, ISGs and scarring  
IFNs are known as antipoliferative and pro-apoptotic molecules. Hence, high 
levels of IFNs in CLE may suggest reduced angiogenesis, proliferation, 
increased apoptosis and consequently, dysregulation of repair mechanism. A 
combination of these factors may explain the permanent scarring observed in 
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CDLE patients. GBP-1, an ISG, has been shown to be highly expressed in 
lesional skin of CLE patients. Interestingly, high expression of GBP-1 has 
been linked with reduced angiogenesis in certain cancers (Naschberger et al., 
2008). IFI16 protein, another ISG, is associated with cellular senescence in 
dermal fibroblasts and endothelial cells. This protein has been shown to 
induce growth arrest in human dermal fibroblasts by negatively regulating the 
hTERT gene (Song et al., 2010). The destruction of the stem cell niche in the 
bulge region of the hair follicle by cytotoxic T lymphocytes and CXCR3+ T 
lymphocytes containing cytotoxic granzyme B+ granules may play a major 
role in scarring DCLE; as these cells were found in skin biopsies from 
scarring CDLE lesions (Wenzel et al., 2005b; Wenzel et al., 2007).     
   
1.5.7 TNFα in LE inflammation 
TNFα plays an important pathogenic role in many inflammatory skin diseases 
as evidenced by the success of TNFα inhibition in a range of conditions, 
including psoriasis and inflammatory bowel diseases. TNFα is produced by 
many cell types, including keratinocytes and signals through the membrane-
bound TNF receptor (TNFR) made up of TNFR1 and TNFR2. The binding of 
TNF to TNFR1 results in the interaction with TNFR-associated death domain 
(TRADD). TRADD serves as a platform for recruitment of downstream 
mediators, including Fas-associated death domain (FADD), receptor-
interacting protein-1 (RIP-1) and TNF-receptor associated factor-2 (TRAF-2). 
TRAF-2 is involved in the recruitment of transcription factors, such as NF-kB 
and JNK while FADD activates the apoptotic pathway (Postal and 
Appenzeller, 2011; Yu et al., 2013). TNFα is significantly increased in CLE 
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lesion (Popovic et al., 2005; Wittmann, 2011). Elevated TNFα production is 
associated with UV irradiation (Casciola-Rosen and Rosen, 1997); increased 
TNFα production has been shown to correlate with high membrane 
expression of Ro (SS-A) and La (SS-B) antigen in human keratinocytes 
(Dorner et al., 1995). High levels of TNFα have been reported in sera and 
skin lesions of SCLE patients. IL-18 induced apoptosis in keratinocytes from 
CLE patients has been attributed to high autocrine TNFα production by these 
cells (Wang et al., 2008). Another evidence implicating TNFα in the 
pathogenesis of CLE is the polymorphism observed at -308A TNFα promoter 
region (Werth et al., 2000). Many studies have shown increased serum level 
of TNFα in patients with active SLE (Aringer et al., 2002; Nordstrom and 
Eriksson, 2012) while others have either observed no significant change or 
that the increased serum level was present in inactive stage of the disease, 
which suggests a role for TNFα in the remission of the disease (Rana et al., 
2012). Despite its expression in LE, cases of drug-induced lupus with 
increased formation of ANA have been reported in patients receiving anti-
TNFα therapy (Moustou et al., 2009; Williams and Cohen, 2011). Increased 
titres of anti-dsDNA antibodies have also been found in rheumatoid arthritis 
patients receiving anti-TNFα therapy. In vitro studies have shown that TNFα 
is capable of downregulating IFNα production in pDCs (Palucka et al., 2005) 
and IFNλ in human dermal fibroblasts (Alase, 2013). We also observed that 
TNFα acts as negative regulator of IFNλ response in human primary 
keratinocytes. As observed in SLE patients, TNFα may act as a repressor of 
uncontrolled or abnormal production of IFNs in LE (Lee et al., 2009; Palucka 
27 
 
et al., 2005). According to available reports, TNFα may be acting as both pro 
and anti-inflammatory cytokine in the context of CLE. 
1.6 Epidermal hyperproliferation and tissue repair 
1.6.1 Psoriasis: Brief overview 
Psoriasis (psoriasis vulgaris) is an immune-mediated, chronic inflammatory 
skin disease affecting about 2 to 3% of people worldwide (Hao, 2014; Lowes 
et al., 2014). Psoriasis was initially thought to be an inflammatory disease of 
the skin resulting from just dysfunctional hyperproliferative epidermal 
keratinocytes (Raut et al., 2013). Psoriasis also affects the nails and the 
joints and has recently been discussed as an independent risk factor for 
other conditions, including coronary heart disease, depression and metabolic 
syndrome (Nickoloff et al., 2007). Histological pictures of psoriatic lesions 
show thickened epidermis (acanthosis), parakeratosis, hypogranulosis, 
presence of infiltrating T cells in the dermis, dilated blood vessels in the 
papillary dermis and presence of neutrophils and CD8+ T cells in the 
epidermis (Fujita, 2013). Many factors, such as injury, trauma (Koebner 
effect), medication, infection and Toll-like receptor 7 (TLR7) agonist, 
imiquimod have been identified as possible triggers for psoriasis. The 
pathogenesis of psoriasis is complex involving both innate and adaptive 
immune responses. Cytokines produced by activated T-cells and dendritic 
cells, such as TNF-α, IFNγ, IL-17 and IL-22 are capable of inducing 
inflammatory molecules and altering differentiation pathway in keratinocytes 
(Griffiths and Barker, 2007; Nograles et al., 2008). Despite the important role 
played by T helper 1 (Th1) cells in the pathogenesis of psoriasis, it is now 
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clear that Th17 cells play a key role in the disease and these findings are 
supported by clinical studies targeting IL-17 (e.g. biologics, such as 
secukinumab) (Fujita, 2013). IL-22 is one of the main T-cell derived 
mediators involved in skin pathology in psoriasis and IL-22 impacts on the 
production of CCL2, induction of genes involved in cell-cycle progression, 
such as cyclin D1 and the expression of β-defensins (HBD-2 and HBD-3) 
(Kubo, 2013; Lew et al., 2004). Th17, Th22 and innate lymphoid cells type 3 
(ILC3) have been identified as the main producers of IL-22 in inflamed skin 
(Duhen et al., 2009; Eyerich et al., 2009; Trifari et al., 2009). In addition to 
induction of antimicrobial peptides, IL-22 triggers regenerative and 
proliferative programme in epithelial cells; hence, its role in epidermal 
hyperproliferation (Eyerich et al., 2009; Tohyama et al., 2009). STAT3 is the 
main transcription factor activated by IL-22 and aberrant activation of STAT3 
has been reported in epidermis of psoriatic lesions (Lew et al., 2004; Sestito 
et al., 2011).  
 
1.6.2 Interleukin 22 (IL-22)  
IL-22 is a member of the IL-10 family of cytokines; consisting of IL-10, IL-19, 
IL-20, IL-22, IL-24, IL-26 and IFNλ (I, II and III). IL-22 exerts its activities by 
binding to its heterodimeric receptor complex comprising IL-22R1 and IL-
10R2, and inducing the activation of STAT3 (Wolk et al., 2005; Xie et al., 
2000). Canonical IL-22 signalling pathway is shown in Figure 1.4. Activation 
of STAT1, STAT5 and MAPK pathways has also been reported (Lejeune et 
al., 2002). The cellular effect of IL-22 is thought to be restricted to 
hepatocytes and epithelial cells; an observation, which correlates with tissue 
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restricted expression of the IL-22R1 (Wolk et al., 2004; Wolk et al., 2005). 
Although IL-10R2 protein is ubiquitously expressed, cellular responsiveness 
to IL-22 is determined by the expression of IL-22R1. Leukocytes and cells of 
hematopoietic origin do not express IL-22R1 and are therefore non-
responsive to IL-22. There is a soluble IL-22R2 referred to as IL-22 binding 
protein (BP), a natural antagonist, which acts as a decoy receptor and has 
been shown to prevent the binding of IL-22 to its receptor in vitro (Wolk et al., 
2006) and has a binding affinity to IL-22 up to ten times higher than that of IL-
22 to IL-22R1 (Wolk et al., 2007). IL-22 is produced mainly by Th17, Th22, 
NK22 and ILC3s (Kumar et al., 2013). High number of CD90, CCR6, CD127 
and RORγt-expressing ILC3s has been reported at mucosal surfaces during 
infections (Van Maele et al., 2014). These cells produce large amount of IL-
22 in response to IL-23 stimulation (Longman et al., 2014; Van Maele et al., 
2014). IL-22 is associated with increased cell proliferation, reduced apoptosis 
and reduced fibrosis in liver cells. The ability of IL-22 to act as survival factor, 
by activating the anti-apoptotic and pro-survival pathway in hepatocytes has 
been reported (Radaeva et al., 2004). IL-22 promotes proliferation, migration 
and the production of matrix metalloproteinase (MMP)-9 in human 
keratinocytes, fibroblasts-like synoviocytes and gastric cancer cells through 
the activation of the PI3K/AKT/mTOR signalling pathway (Ji et al., 2014; 
Mitra et al., 2012b). IL-22 has both inflammatory/pathological and 
immunomodulatory roles. As a pathological agent, it is involved in active 
induction and recruitment of chemokines and cytokines, such as CXCL1, 
CXCL2, CXCL5, IL-6, IL8 and TNFα to the site of inflammation (Cobleigh and 
Robek, 2013). IL-22 is also involved in the recruitment of neutrophils and 
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MMP production. Immunoregulatory activity of IL-22 includes: induction of IL-
10 and TGFβ in responsive cells (Lim and Savan, 2014). IL-22 is a unique 
cytokine in that it lacks autocrine and paracrine activities but rather functions 
as a transmitter of information from leukocytic to non-leukocytic cells. IL-22 
has protective role in both humans and mouse. It enhances the proliferative 
ability of intestinal epithelial cells and maintains integrity of epithelial barriers 
by preventing dissemination of pathogenic bacteria (Zenewicz and Flavell, 
2011). During hepatitis infection, IL-22 prevents liver damage by activities of 
IFNs and IFN-producing cells. This suggests that IL-22 is capable of 
counteracting or limiting the destructive effects of these cytokines (Zenewicz 
et al., 2007). IL-22 has been shown to be protective against fibrosis in 
various organs of the body (Muhl et al., 2013) and it is involved in liver cells 
regeneration (Brand et al., 2007). Decreased levels of IL-22 protein have 
been reported in the serum of SLE patients (Pan et al., 2009); however, few 
studies have also linked IL-22 to the pathogenesis of SLE. Yu et al. reported 
a relationship between genetic variation in IL-22 copy number and the risk of 
SLE (Yu et al., 2011). This report however requires further studies to confirm 
the mechanism of action of IL-22 in the pathogenesis of SLE. The “repair 
promoting” role of IL-22 on epithelial cells makes it a promising therapeutic 
molecule for conditions with abnormal scarring (Eyerich et al., 2009).   
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Figure 1.4: IL-22 signalling pathway 
IL-22 binds to its heterodimeric receptor complex comprising IL-22R1 and IL-
10R2. This binding results in phosphorylation Jak1 and Tyk2, leading to the 
activation of STAT3 and to a lesser extent the AKT/mTOR pathway. 
Activation of MAPK pathway (MEK1/2, ERK1/2, JNK and p38) has also been 
described (Pan et al., 2013). Downstream effects of IL-22 include 
transcription of genes such as SOCS3, MMPs, and AMPs that are involved in 
inflammation, proliferation, migration and angiogenesis. Adapted from (Sabat 
et al., 2014). 
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1.6.3 Transforming growth factor β (TGFβ) in tissue repair 
TGFβ was initially described as a secreted polypeptide with the ability to 
induce fibroblasts growth and collagen production (Roberts et al., 1986). 
TGFβ is a multifunctional cytokine that is involved in the regulation of 
essential cellular functions, such as apoptosis, extracellular matrix production, 
proliferation, angiogenesis and epithelial-mesenchymal transition (EMT) (ten 
Dijke and Hill, 2004). There are three isoforms of TGFβ identified in 
mammalian tissue: TGFβ1, TGFβ2 and TGFβ3 and they all share the same 
receptor (Kubiczkova et al., 2012). However, TGFβ1 is the most abundant 
and ubiquitously expressed isoform. TGFβ exerts its biological effect by 
binding to and bringing together its receptors, type I (TβRI) and type II (TβRII) 
receptor serine/threonine kinases on cell surface (Takekawa et al., 2011). 
Binding of TGFβ to its receptor, results in the phosphorylation of TβRII, which 
in turn activates TβRI. Activation of TβRI leads to propagation of signal 
through the phosphorylation of R-Smad, mainly Smad2 and Smad3, which 
are cytoplasmic transcription factors (Shi and Massague, 2003). These 
phosphorylated Smad proteins undergo heterotrimerization and form a stable 
heterometric complex with a common partner, Smad4 (Shi and Massague, 
2003). Cellular responses to TGFβ are dependent on the cell type and 
physiological conditions (Kubiczkova et al., 2012). All the three isoforms 
(TGFβ1, 2, 3) have been described as inhibitors of proliferation in most cell 
types and are known to induce apoptosis in epithelial cells. However, in 
mesenchymal cells, such as fibroblasts, they induce proliferation and 
production of extracellular matrix, and they also induce fibrotic response in 
many tissues in vivo (Leask and Abraham, 2004). One of the major functions 
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of TGFβ is the regulation of cell cycle progression by modulating the 
transcription of cell cycle regulators (Kubiczkova et al., 2012). TGFβ plays a 
key role in wound healing and scar formation; some of which include: 
regulating the production of proteases, protease inhibitors, chemokines, 
extracellular matrix (ECM) and proliferation of stem cells (Wang et al., 2007). 
Foetal wound that heals without scar formation has been shown to express 
reduced and transient amount of TGFβ isoforms and their receptor in 
comparison to adult wounds (Cowin et al., 2001).  
1.7 Some regulatory molecules and signalling pathways involved in 
inflammation 
1.7.1 Silencer of cytokine signalling (SOCS) 
Suppressor of cytokine signalling (SOCS) proteins are intracellular molecules, 
which regulate the responses of immune and tissue cells to cytokines. SOCS 
were initially discovered as inhibitory regulators of the cytokine-induced JAK-
STAT pathway of cytokine receptor signalling. SOCS proteins are unstable 
and are encoded as early response genes. Most of these proteins are 
induced by cytokine; hence, they act as negative regulators of cytokine 
signalling. The SOCS proteins are not highly expressed in unstimulated cells 
or tissues, but are encoded by highly inducible genes, which are rapidly 
transcribed upon exposure to cytokines, often in a phosphorylated STAT-
dependent manner (Alexander, 2002).  
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1.7.1.1 SOCS1 and SOCS3 
SOCS1 and SOCS3 are the best characterised members of the SOCS 
protein family. SOCS1 is a natural antagonist of the STAT1 signalling 
pathway and it is inducible by IFNs as a negative feedback mechanism 
(Tomasello et al., 2014). SOCS3 carries out its inhibitory function by first 
binding to the receptor and then interacts with phosphorylated activation loop 
and catalytic pocket through the src homology (SH) domain and kinase 
inhibitory region (KIR) respectively (Yoshimura et al., 2007). A similar 
mechanism of interaction between SOCS1 and JAK2 is proposed for the 
inhibition of IFNγ signalling. However, another mechanism involving KIR 
binding to the surface of JHI rather than catalytic pocket and inhibiting 
phosphate transfer has been reported (Babon et al., 2012). SOCS3 is able to 
directly inhibit the catalytic domain of JAK1, JAK2 and TYK2 but not JAK3 
(Inagaki-Ohara et al., 2013). SOCS3 acts mainly as regulator of STAT3 
activation in response to cytokines using glycoprotein 130 (gp130) and other 
related receptors. gp130 is a component of the receptor complex for 
cytokines belonging to the IL-6 family, such as IL-6, IL-27, oncostatin M 
(OSM), leukaemia inhibitory factor (LIF) and IL-11 (Carow and Rottenberg, 
2014; Yoshimura et al., 2007). SOCS3 is also capable of inhibiting STAT3 
activation in response to cytokines, growth factors and hormones in a gp130 
independent manner. SOCS3 also interacts with other receptors that do not 
activate STAT3 (Carow and Rottenberg, 2014). Despite the ability of SOCS3 
to bind and inhibit JAK catalytic activity, its preference for binding to gp130 
receptor has been demonstrated in mice (Bergamin et al., 2006). STAT3 
activation is essential in Th17 differentiation; however, SOCS3 has been 
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identified as a major negative modulator of IL-23-mediated STAT3 
phosphorylation during Th17 generation (Chen et al., 2006; Milner et al., 
2008). High expression of SOCS3 has been reported in synovial fibroblasts 
of rheumatoid arthritis (RA) patients and skin of patients with psoriasis 
(Madonna et al., 2012; Shouda et al., 2001). Although SOCS3 is well known 
as a negative regulator of STAT3 signalling, its role in the regulation of 
STAT1 pathway has also been reported. SOCS3 deficient cells showed 
increased expression of STAT1 signature genes in response to IL-6 (Croker 
et al., 2003). Herpes simplex virus (HSV) induced SOCS3 expression has 
been shown to suppress type I IFN production and responses (Yokota et al., 
2005). SOCS3 also acts as negative regulator of IFNβ response in 
macrophages (Carow and Rottenberg, 2014).   
  
1.7.2 Mitogen activated protein kinases (MAPK) 
There are fourteen (14) MAPKs described so far in mammalian cells; 
however, three (3) main families- extracellular signal-regulated kinases (ERK; 
ERK 1 and 2), the p38 MAPKs (α, β, δ and γ) and the c-Jun NH2-terminal 
kinases (JNK; JNK1, JNK2 and JNK3) have been studied extensively (Arthur 
and Ley, 2013; Chang and Karin, 2001). The MAPK pathway is one of the 
most evolutionary conserved, playing key roles in both innate and adaptive 
immunity (Zhang and Dong, 2005). The pathway was initially described as 
proteins activated by growth factors (Krzyzowska et al., 2010) and they 
control fundamental cellular processes, such as proliferation, cellular survival, 
apoptosis, metabolism, mitosis and differentiation. MAPK signalling cascade 
is organised into three tiers: MAPK kinase kinase (MAP3K), MAPK kinase 
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(MAP2K) and MAPK, which are sequentially activated in order to achieve 
downstream gene expression (Meister et al., 2013) as shown in Figure 1.5.  
 
Figure 1.5: MAPK cascades  
There are three main mammalian MAPKKK–MAPKK–MAPK protein kinase 
cascades. The ERK pathway is commonly activated by growth factors while 
the JNK and p38 pathways are activated by environmental stress, including 
osmotic shock, ionizing radiation. Many nuclear transcription factors, such as 
MNK, MEFS and NFAT4 are substrate for MAPKs. The activation of these 
transcription factors results in nuclear translocation and subsequent 
biological effects, such as proliferation, apoptosis, inflammation and growth. 
Adapted from (Morrison, 2012; Roberts and Der, 2007).  
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1.7.2.1 Extracellular signal-regulated protein kinase (ERK) 
ERK1/2 are ubiquitously expressed proteins that form part of the Ras-Raf-
MEK-ERK signalling cascade with important roles in cellular processes, such 
as cell survival, cell adhesion, cell migration, transcription, cell proliferation, 
differentiation and cell cycle progression (Roskoski, 2012a). The MAP3K 
component of ERK signalling cascade is the Raf serine/threonine kinase (c-
Raf-1, A-Raf and B-Raf), which is activated by Ras-GTP. Raf kinases 
phosphorylate and activate MEK1 and MEK2. Activation of these dual-
specificity protein kinases results in the downstream phosphorylation of 
tyrosine and threonine in ERK1/2, their only known substrate (Roskoski, 
2010). While it is known that Raf kinase and MEK1/2 have restricted 
substrate specificity, activation of ERK1/2 results in the phosphorylation and 
activation of over 200 cytoplasmic and nuclear substrates (Roskoski, 2012b). 
It is well known that the activation of ERK1/2 results in inhibition of apoptosis; 
particularly in response to: TNF, Fas ligand, osmotic stress, hydrogen 
peroxide and radiation (Lu and Xu, 2006). Inhibition of ERK1/2 has been 
shown to promote apoptosis; however, the mechanism by which ERK1/2 
inhibit apoptosis is somewhat complicated and depend on cell type. One 
mechanism by which ERK promotes cells survival is by enhancing the activity 
of anti-apoptotic molecules, such as Mcl-1, a member of the Bcl-2 family 
(Domina et al., 2004). ERK1/2 is also capable of regulating the activities of 
anti- and pro-apoptotic transcription factor, such as cAMP response element 
binding protein (CREB) (Bonni et al., 1999). Although ERK1/2 are well known 
as pro-survival factor, they can also function in a pro-apoptotic manner. It has 
been suggested that ERK1/2 activation is involved in neurodegeneration and 
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inhibition of ERK1/2 pathway attenuates apoptosis and G2-M arrest induced 
by mitogen or UV (Lu and Xu, 2006). 
 
1.7.2.2 P38 MAPK 
P38 was discovered as evolutionarily conserved protein kinase that can be 
activated by lipopolyssacharide (LPS) and IL-1 (Han et al., 1994; Lee et al., 
1994). Activation of the p38 signalling pathway can be triggered by a variety 
of stimuli; hence, the receptor and downstream substrate are diverse. 
MAP3Ks involved in the activation of p38 signalling include: apoptosis signal-
regulating kinase (ASK) 1, TAK1, MTK1 and mixed lineage kinase (MLK) 2/3 
(Yang et al., 2014). Phosphorylation and activation of these kinases result in 
activation of MAP2Ks, such as MKK3 and MKK6 which are directly involved 
in the activation of p38. Transcription factors activated downstream of p38 
include: Elk1, STAT1, MAPK-activated protein kinase 2/3 (MK2/3), p53 and 
ETS (Morrison, 2012). Activation of the p38 pathway contributes to 
inflammation, cytokine production, cell differentiation, cell cycle regulation, 
cell proliferation and apoptosis (Cuadrado and Nebreda, 2010; Yang et al., 
2014). In human skin fibroblasts, activation of p38 has been shown to lead to 
rapid dephosphorylation of MEK1/2 resulting in apoptosis. On the contrary, 
inhibition of p38 prevents dephosphorylation of MEK1/2 and apoptosis (Li et 
al., 2003). Uncontrolled activation of p38, particularly in the absence of 
mitogen stimuli results in apoptosis, whereas, inhibition of this pathway 
confers resistance to stress-induced cell death (Takekawa et al., 2011). P38 
also plays a role in mRNA stability of some cytokines, such as TNFα, IL-6 
and IL-1β (Yang et al., 2014). 
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1.7.2.3 c-Jun N-terminal Kinases (JNK) 
JNK pathway is activated by stress factors (heat, oxidative stress and DNA 
damage), cytokines and growth factors. The JNK stress pathway is involved 
in intracellular processes, such as apoptosis and cell survival (Dhanasekaran 
and Reddy, 2008; Morrison, 2012). JNK signalling cascade involves the Rho 
family of GTPases, Cdc42 and Rac (Johnson and Nakamura, 2007). JNKs 
are directly activated by dual-specificity kinases, MKK4 and MKK7, and their 
activation lead to downstream phosphorylation and activation of c-Jun and 
ATF2 transcription factors and Bcl family members (Krzyzowska et al., 2010; 
Lei and Davis, 2003).  
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1.8  Hypothesis  
This project is placed in the overall context of improving our knowledge of 
CLE pathogenesis and in particular scarring versus a non-scarring outcome 
of CLE inflammation.  
Experimental designs for this work were based on the following hypothesis: 
IL-22 is a key molecule that strongly activates STAT3 which is actively 
involved in normal wound healing. IFNs on the other hand are strong 
activators of STAT1 signalling, which has been implicated in increased 
apoptosis and reduced cell proliferation. CLE, in particular CDLE is 
characterised by increased apoptosis and enhanced production of IFNs and 
ISGs. Based on the understanding of the fact that IL-22 and IFNλ share a 
second receptor, IL-10R2, and the contrasting roles of these cytokines with 
regards to proliferation, it was hypothesised that the balance between IL-
22/STAT3 and IFNλ/STAT1 pathways may be very important in determining 
scarring and non-scarring outcomes in inflammatory skin diseases. 
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1.9 Aims  
The specific aim of this project was to investigate the regulation and 
influence of IL-10 family members on epidermal and dermal responses which 
could influence the overall outcome of inflammation resolution and repair. 
  
This aim can be sub-divided as follows: 
 
 To understand how IFNλ and IL-22 are produced, regulated and 
functionally impact on dermal and epidermal cells.   
 To understand the interaction between IL-22, STAT3 signature genes, 
IFNs and ISGs in the context of inflammatory and repair related 
cutaneous responses. 
 To understand, if any, the counter regulatory effect of IL-22 versus 
IFNλ on signalling and downstream activities in skin resident cells. 
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CHAPTER 2: MATERIALS AND METHODS 
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2 Materials and Methods 
2.1 Ethics 
Keratinocytes and dermal fibroblasts were isolated and cultured from skin 
tissue from individuals undergoing cosmetic surgery (face lift). Patients gave 
informed written consent and ethical approval was granted by the University 
of Bradford ethics committee. Skin tissue was prepared on the day of 
collection. CLE keratinocytes were hair-derived and provided from Hannover 
Medical School, Hannover, Germany. Patient derived biopsies were collected 
and processed in Leeds under the CONVAS ethics (REC 10/H1306/88).  
2.2 Reagents/cytokines 
Phosphate buffered saline (PBS) (Gibco/life technologies, Paisley, UK), 
Ethelenediaminetetraacetic acid (EDTA) (Lonza, Slough, UK), 0.25% trypsin 
(Gibco), trypsin/EDTA (TE) (Lonza), Trypsin neutralising solution (TNS) 
(Lonza), Penicillin/Streptomycin and Fetal bovine serum (FBS) (PAA/GE 
healthcare, Sommerset, UK), Dulbecco's modified eagle's medium (DMEM) 
(PAA), Keratinocytes growth medium (KGM) with supplements (Promocell, 
Heidelberg, Germany), CryoSF freezing medium (Promocell), Fetal calf 
serum (promocell), recombinant human (rh) IFNα2a (Merck/Calbiochem, 
Merck Serono Ltd, Middlesex, UK), rhIFNλ1 and rhIL-22 (ebioscience, 
Hatfield, UK), rhIFNγ and rhTNFα (Immunotools, Friesoythe, Germany), poly 
I:C and poly dA:dT (Invitrogen, Life Technologies), rhTGFβ1 (Peprotech, 
London, UK).  Primers were purchased from Qiagen (Manchester, UK) and 
Sigma-Aldrich (Dorset, UK). Antibodies were purchased from Abcam 
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(Cambridge, UK), Cell signaling (Hitchin, Hertfordshire, UK), RnD systems 
(Abingdon, UK), Santa Cruz Biotechnology, Insight Biotechnology (Middlesex, 
UK) and Biolegend (London, UK). 
Table 2.1: List of primers 
Primer Sequence or ID Company 
Col1A1 QT00037793 Qiagen 
Col3A1 QT00058233 Qiagen 
Col4A2 QT01329461 Qiagen 
Col7A1 QT00998886 Qiagen 
CXCL-9 QT00013461    
 
Qiagen 
CXCL10 QT01003065 Qiagen 
GBP-1 QT00011641 Qiagen 
IFI16 QT00066675 Qiagen 
IFNλ1 QT00222495   
 
Qiagen 
IFNλR1 QT00034440 Qiagen 
IL-22 QT00034853    
 
Qiagen 
IL-22R1 QT00018550    
 
Qiagen 
IL-22R2 QT00021539    
 
Qiagen 
JUNB QT00201341 Qiagen 
MxA 
 
QT00090895 
 
Qiagen 
SOCS1 QT00202475 Qiagen 
SOCS3 F-5'-AGACTTCGATTCGGGACCA-3’  
R-5’-AACTTGCTGTGGGTGACCA-3’ 
Sigma 
VEGF-A QT01010184 Qiagen 
U6 F- 5’ CTCGCTTCGGCAGCACA 3’ 
R- 5’ AACGCTTCACGAATTTGC 3’ 
Sigma 
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Table 2.2: Primary antibodies used 
Antibodies Source Clone Company 
GAPDH Mouse Monoclonal Santa Cruz 
IFNλR1 (Western 
blotting) 
Rabbit Polyclonal Abcam 
IFNλR1 (PE; flow 
cytometry) 
Mouse Monoclonal Biolegend 
IL-22R1 (Western 
blotting) 
Rabbit Polyclonal Abcam 
IL-22R1 (APC; Flow 
cytometry) 
Mouse monoclonal RnD 
MxA(ab198178) Rabbit Polyclonal Abcam 
P38(#9212) Rabbit Polyclonal Cell signaling 
Phospho 
p38(#9311) 
Rabbit Polyclonal Cell signaling 
p42/44 (ERK) 
(#9102) 
Mouse Monoclonal Cell signaling 
Phospho p42/44 
(ERK)(E10,#9106) 
Mouse Monoclonal Cell signaling 
Phospho 
STAT1(#9171) 
Mouse Monoclonal Abcam 
STAT1(#9172) Rabbit Polyclonal Cell signaling 
Phospho 
STAT3(#9131) 
Rabbit Polyclonal Cell signalling 
STAT3(#4904) Rabbit Polyclonal Cell signaling 
 
Table 2.3: Secondary antibodies used 
 Antibodies Source Company 
Donkey anti-mouse 
HRP 
Donkey Santa cruz 
Donkey anti-rabbit 
HRP 
Donkey Santa cruz 
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2.3 Cell culture 
 
2.3.1 Keratinocytes isolation 
Skin samples from cosmetic surgery were stripped of fat using scissors or 
razor blades and were cut up into approximately 1.0 cm2 pieces. Cut skin 
samples were thoroughly washed in PBS. Skin was incubated overnight 
submerged (epidermis side up) in 0.25% Trypsin at 4°C and then heated to 
37°C for 30 minutes prior to removal of the epidermis. The epidermis was 
removed and incubated for 5 minutes at 37°C in a water bath in 1 ml 0.05% 
Trypsin/EDTA (TE) and vortexed for 1 minute thereafter.  The resulting 
trypsinised cell suspension was carefully aspirated and transferred into 
serum-containing media to neutralise TE. Incubation in TE was repeated 
twice more. Cells- containing suspension was centrifuged for 5 minutes at 
1000 rpm to pellet cells. The cell pellet was resuspended in KGM-2/DMEM 
(ratio 2:1) and cells were seeded in T75 flask. DMEM contained 5% or 10% 
fetal calf serum (FCS; Promocell) or fetal bovine serum (FBS; PAA). 
Alternatively, cell pellet was resuspended in T75 flask coated with type IV 
collagen (Sigma Aldrich, Dorset, UK). Media was replaced with complete 
KGM two days after initial seeding and cells were fed every 2-3 days until 
subconfluent. 
 
2.3.2 Fibroblasts isolation 
After fat removal (as above) the skin sample was placed in a 6-well plate with 
the dermis facing down. In skin samples where the epidermis was removed, 
the remaining ‘dermal’ component was flipped over such that the sub-
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epidermal part was allowed to touch the surface of the T75 culture flask. 1 ml 
or 10 ml of DMEM containing 4.5 g/L glucose and L-Glutamine (Lonza) and 
supplemented with 10% FCS or FBS, 0.5 mg/ml streptomycin and 100 U/ml 
penicillin was added depending on whether a plate or culture flask was used. 
The plate or flask was placed in 37oC, 5% CO2 incubator for fibroblasts to 
grow out. Culture medium was changed every 2-3 days or after 5 days for 
dermis cultured in a T75 flask. Fibroblasts began to grow out after 7 days of 
continuous culture. Cells were then trypsinised and cultured in a T75 culture 
flask. Cells were usually used between passages 2 and 6. 
2.4 Cells passaging 
Cells in culture flasks were usually split when they reached between 80 and 
90% confluence. Cells were washed under the safety cabinet with 5-10 ml 
pre-warmed (PBS, Gibco), depending on the size of flask, by shaking the 
flask gently for about 4 times. PBS was removed and 3 ml or 5 ml of TE for 
T75 and T225 respectively was added to the cells. The flask was transferred 
to the incubator for about 5 minutes in order to detach cells from the flask. 
For keratinocytes, cells were first treated with 5 ml EDTA and flask was 
transferred to the incubator for 5 minutes in order to break cell-cell interaction. 
At this stage, the cells have become single cells and round. EDTA was 
removed and TE added as above but for about 3 minutes. TNS or serum 
containing DMEM was added to keratinocytes and fibroblasts respectively in 
order stop the activity of trypsin. Amount added was equal to the volume of 
TE. Cells were transferred into 15 ml Falcon tube and centrifuged at 1500 
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RPM for 3 minutes. Cell pellet was either resuspended in culture medium 
(and plated for experiments or further culture) or frozen as described below.  
2.5 Freezing and thawing of cells 
Cell suspension obtained in the context of cell passaging was transferred to a 
15 ml Falcon tube. Cells were centrifuged at 1500 RPM for 3 minutes. 
Supernatant was discarded and CryoSFM freezing medium (1 ml per 1-2 
x106 cells) was added to the cell pellet. Cells were resuspended and 
transferred into the freezing vial. The vial was transferred into Mr. Frosty 
which was taken to the -80oC freezer overnight before cells were transferred 
into the liquid nitrogen (196oC) until needed.  
To thaw cells, vials containing the cells were left in 37oC water bath until 
almost completely thawed but with a little bit of ice still floating in the vial. 
Cells were transferred into already pre-warmed culture medium in a culture 
flask and the flask transferred into the incubator at 37oC, 5% CO2 for the 
cells to attach to the flask and to continue proliferating until ready for the next 
passage. 
2.6 RNA isolation from cells 
Total RNA was isolated using quick RNA mini-prep kit (Epigenetics, 
Cambridge bioscience, Cambridge, UK). Cells were lysed with 600 µl ZR 
RNA buffer and the lysate was transferred into the Zymo spin IIIC column in 
a collection tube. This was centrifuged at 13000 g for 1 minute and the eluted 
liquid was discarded. This was repeated with 400 µl RNA pre-wash buffer 
(13000 g for 1 minute), 700 µl RNA wash buffer (13000 g for 30 seconds) 
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and 400 µl RNA wash buffer 13000 g for 30 seconds). Thereafter, the Zymo 
spin column was centrifuge at 13000 g for 2 minutes in order to ensure 
complete removal of the wash buffer. The spin column was placed in a 
RNase-free tube and 35 µl of DNase/RNase free water was added directly to 
the column matrix and allowed to stand at room temperature for 1 minute. 
This was centrifuged at 13000 g for 30 seconds. The eluted RNA was either 
stored at 70oC or used immediately in reverse transcriptase (RT) reaction.  
2.7 RNA isolation from animal tissue 
RNA was isolated from tissue biopsies using the Animal tissue RNA 
purification kit (Norgen Biotek, Geneflow limited, Lichfield, UK). Samples 
were initially embedded in optimal cutting temperature (OCT) compound. 
Embedded skin tissue was cut into 100 µm shaves using cryostat. Excess 
OCT was removed physically using scalpels at -20oC. The shaved sample 
was then homogenised by adding 300 µl of buffer RL and sample was 
ground or vortexed vigorously until homogenised. Lysate was transferred into 
RNase-free microcentrifuge tube. 600 µl RNase-free water was added to the 
lysate which was then vortexed. 20 µl of proteinase K was added to the 
lysate and was incubated at 55oC for 15 minutes with intermittent mixing 
(vortex). The lysate was then spun for 1 minute to pellet any cell debris. The 
obtained supernatant was transferred to a new RNase-free microcentrifuge 
tube. 450 µl of 100% ethanol was added to the lysate which was submitted to 
vortexing. 650 µl of lysate with ethanol was transferred into a spin column 
placed on top of a collection tube. The column was centrifuged at 3500 g for 
1 minute. Eluted liquid was discarded and the step was repeated using 400 
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µl of wash solution A (centrifuged for 2 minutes). Thereafter the collection 
tube was placed in a new collection tube. 100 µl of enzyme incubation buffer 
A and 15 µl of DNase I were added to the column and centrifuged at 14000 g 
for 1 minutes. The eluted liquid was put back into the column and was 
incubated at room temperature for 15 minutes. 400 µl of wash solution A was 
added to the column containing DNase I mix and was centrifuged for 1 
minute. Eluted liquid was discarded and the step was repeated with the 
addition of 400 µl of wash solution A. The column was then centrifuged for 2 
minutes in order to thoroughly dry the resin. The column was placed into a 
fresh 1.7 ml elution tube and 50 µl of elution solution A was added to the 
column, which was then centrifuged for 2 minutes at 200 g and subsequently 
for 1 minute at 14000 g. Eluted RNA was stored at -70oC or reverse 
transcribed immediately to cDNA. 
2.8 Reverse transcriptase reaction 
Total RNA reverse transcription was carried out using first strand cDNA 
synthesis kit (Fermentas/ Thermo Fisher Scientific, Loughborough, UK). 10 µl 
of total RNA was transferred to 0.2 ml PCR tube and 1 µl oligo (dT)18 primer 
(15 pmol) was added to it. The tube was heated at 65oC for 5 minutes and 
the following were added to make up a total volume of 20 µl: 4 µl 5x reaction 
buffer, 1 µl ribolock RNase inhibitor (20 U/μl), 2 µl dNTP, 2 µl MuLV reverse 
transcriptase (20 U/μl). The tube was centrifuged at 13000 g for 10 seconds 
and the RT reaction was run as follows: 42oC for 60 minutes, 70oC for 5 
minutes to inactivate the enzymes. The reaction was cooled down at 4oC. 
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cDNA from the reaction was either stored at -70oC or used immediately in 
qRT-PCR reaction.   
2.9 Quantitative real time- polymerase chain reaction (qRT-PCR) 
Quantitech primers were purchased from Qiagen except for SOCS3 and 
U6snRNA primers, which were purchased from Sigma (Table 2.1). cDNA 
amplification was carried out using QuantiFast qRT-PCR kit (Qiagen) and run 
in BioRad cfx connect machine (BioRad). The total reaction volume of 20 μl 
was made up of: 10 μl SYBR green mix (1x final concentration), 6 μl 
DNase/RNase free water, 2 μl primer (1 μM final concentration) and 2 μl 
cDNA (<100 ng/reaction). The reaction was run using the following 
parameters: Initial heat activation, 95oC for 5 minutes; denaturation, 95oC for 
10 seconds; combined annealing and elongation, 60oC for 30 seconds for a 
40 cycle run.  mRNA expression of the gene of interest was normalised to 
U6snRNA mRNA using the ΔΔCT relative quantitation method.  
2.10 Cytokine measurement 
Cell culture supernatants were collected after 24 or 48 hours of continuous 
stimulation of cells and were analysed for secreted IFNλ1, CXCL10 or CCL2 
using commercially available sandwich ELISA kits following manufacturers’ 
protocols (IFNλ1, CCL2; ebioscience) and RnD systems (CXCL10; Abingdon, 
UK). Maxisorp flat-bottom 96-well plates (Nunc, Thermoscientific, 
Cramlington, UK) were coated with 100 μl capture antibody overnight at 4oC 
or room temperature. Coated plates were then washed with at least 250 μl of 
wash buffer (0.05% tween-20; Sigma) in PBS per well for a total of 4 or 5 
52 
 
washes. Plates were blocked with 200 μl block buffer (1% FCS in PBS) or 
reagent diluent (eBioscience). Supernatants were then added and left at 
room temperature for 2 hours. The plates were washed with wash buffer as 
previously done. Detection antibody was then added for either 1 or 2 hours 
depending on the manufacturer’s protocol. Plates were washed with wash 
buffer and then 100 μl of streptavidin (RnD) or avidin (ebioscience) was 
added to the wells for 20 or 30 minutes respectively. Plates were washed 
again and 100 μl substrate solution was added to each well for between 10 
and 20 minutes before stopping the reaction with 50 μl 2N H2SO4. 
Absorbance of each well was measured at 450 nm and corrected at 570 nm 
using ELISA plate reader and data collected using Gen5 software (Biotek, 
Potton, UK) or Magellan 6, 200 series (Tecan, Theale, UK). 
2.11 Flow cytometric analysis   
Human primary keratinocytes or dermal fibroblasts were cultured in 6-well 
plates (Greiner bio-one, Stonehouse, UK). To detach cells for flow cytometry, 
culture supernatants were removed and cells washed with 500 μl warm 1x 
PBS without CaCl2 and MgCl2 (Gibco/life technologies, Paisley, UK). Cells 
were then detached from the culture plate using 250-500 μl Hyqtase (Thermo 
Scientific) or trypsin/EDTA (Lonza) and the reaction was stopped using equal 
volume of trypsin neutralising solution (Lonza). Cells were washed once with 
ice-cold PBS. For surface staining, cells were washed twice with FACS buffer 
(5% BSA/PBS) and centrifuged at 350 g for 5 minutes. Cells were stained 
with APC-conjugated mouse anti-human IL-22R1 antibody (1:10; R&D 
systems) for 30 minutes at 4oC. Cells were then washed twice with FACS 
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buffer and resuspended in 400 µl FACS buffer for analysis. For intracellular 
staining, cells were fixed by resuspending cell pellet in 
fixation/permeabilization buffer (ebioscience) and centrifuged at 500 g for 5 
minutes. Cells were then resuspended in permeabilization buffer 
(ebioscience) for 30 minutes at 4oC. Cells were washed three times with 
FACS buffer and centrifuging at 500 g for 5 minutes after each wash. Cells 
were stained with APC-conjugated mouse anti-human IL-22R1 antibody 
(RnD systems) or PE-conjugated mouse anti-human IFNλR1 antibody 
(Biolegend) in FACS buffer for 30 minutes at 4oC. Appropriate APC-
conjugated (RnD systems) or PE-conjugated isotype (Biolegend) controls 
was used. Cells were washed two times with FACS buffer and centrifuged at 
500 g for 5 minutes. Cells were resuspended in FACS buffer ready for 
analysis. For flow cytometry, BD LSRFortessa (BD Biosciences, Oxford, UK) 
was used. Data collected were further analysed using FACSdiva software 
(BD Biosciences). 
2.12 Protein concentration determination 
Protein concentrations in cell lysates were determined by Bradford assay 
(Pierce/Thermo Fisher Scientific, Cramlington, UK) using manufacturer's 
protocol. Titrated concentrations of bovine serum albumin were used as 
standard. 5 μl of standards and lysates were aliquoted into a flat bottomed 
96-well plate (Nunc). 200 μl Coomassie protein reagent was added to the 
wells. The intensity of colour change from violet red to blue indicated the 
amount of protein present. Absorbance was measured at 560 nm using 
Magellan 6, 200 series (Tecan). 
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2.13 Western blotting 
Keratinocytes and dermal fibroblasts cultured in 6-well plates were lysed with 
CelLytic M lysis buffer (Sigma-Aldrich) containing protease inhibitor cocktail 
(Roche Applied Bioscience, Rotkreuz, Switzerland) to prevent protein 
degradation and phosphatase inhibitor (Thermo Scientific) to preserve 
phosphorylated proteins. Protein concentration was determined by Bradford 
assay (Thermo Scientific). 30 µg of total protein was separated according to 
their molecular weight using 4-20 % gradient (any kDa) mini protean gel 
(BioRad). Proteins were blotted onto 0.2 μm PVDF trans-blot pack (BioRad) 
and membrane blocked in 5% dried semi-skimmed milk in PBS or TBS 
containing 0.1% Tween-20 (PBST) for 1 hour on a shaker at room 
temperature. For phosphorylated experiment, membrane was probed with 
rabbit anti-human pSTAT1 (1:1000), STAT1 (1:1000), phospho p38 (1:1000), 
mouse anti-human pERK (1:2000), p38 (1:1000) or GAPDH (1:3000) in 
TBST containing 5% bovine serum albumin (BSA) overnight at 4oC with 
gentle shaking. Rabbit anti-human MxA (1:1000), rabbit anti-human IL-22R1, 
rabbit anti-human IFNλR1 (1:1000) and GAPDH were used in 5% milk PBST 
overnight at 4oC with gentle shaking. Donkey anti-rabbit and donkey anti-
mouse HRP-conjugated secondary antibodies were used at 1:5000 and 
1:3000 respectively in 5% milk PBST or 0.5% TBST for 1 hour at room 
temperature. Membranes were incubated in enhanced chemiluminiscence 
(ECL; BioRad) for 2 to 5 minutes at room temperature and protein bands 
were detected using Chemidoc imaging system (Bio-Rad). For a repeat 
Western, membranes were stripped at room temperature for 15 minutes 
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using stripping buffer (Thermo scientific) and blocked for 30 minutes prior to 
probing with primary antibody.    
2.14 Scratch assay 
Keratinocytes or dermal fibroblasts were seeded into 24-well plates (Greiner 
bio-one) and allowed to grow to 90-95% confluence. Cells were starved in 
KGM without hydrocortisone and EGF for keratinocytes or DMEM without 
serum for dermal fibroblasts for 24 hours. Using 200 μl yellow pipette tips 
(Greiner bio-one), a single line scratch was created in each well of the 24-
well plates containing cells. Cells used for migration experiments were 
treated with 5 µg/ml mitomycin C for 2 hours before scratching in order to 
stop cell proliferation. Cells were washed twice with warm PBS in order to 
remove cell debris. Cells were covered with culture media depending on the 
growth condition to be examined. For keratinocytes, the four culture 
conditions were: Full growth medium containing hydrocortisone, EGF (+/+) 
and KGM without hydrocortisone (+/-), KGM with EGF (-/+) and KGM without 
hydrocortisone and EGF (-/-). Keratinocytes were then either untreated or 
treated with IL-22 or IFNλ1 while fibroblasts were treated with IL-22, IFNα or 
IFNλ1 for 48 hours with images of the cells taken at 0, 24 and 48 hours using 
4x objective on a Zeiss microscope and Nikon camera. Results were 
analysed using Wimscratch software (Wimasis, Munich, Germany) or 
Tscratch software (www.cse-lab.ethz.ch/software.html). 
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2.15 Cell trace proliferation assay 
Human primary keratinocytes and dermal fibroblasts were harvested and 
resuspended in KGM or serum-free DMEM respectively. Cells were then 
stained with cell trace violet (Molecular probes/Life technologies) away from 
the source of light (2 µl cell trace to 1 million cells in 1 ml media). Cells were 
incubated in a water bath at 37oC for 30 minutes to allow the cells to take up 
the dye. 10 ml KGM or DMEM containing 10% FBS was then added to the 
keratinocytes or fibroblasts respectively and cells were incubated in water 
bath at 37oC for 10 minutes in order to remove any unbound dye. Cells were 
centrifuged at 350 g for 5 minutes. Keratinocytes were resuspended in KGM 
while dermal fibroblasts were resuspended in DMEM containing 1% serum. 
Cells were plated in 6-well plates and were either treated with cytokines or 
untreated for 72 hours.  Some cells were used for the day 0 (0 hour) analysis. 
Cells were trypsinised and analysed after 72 hours using flow cytometry. For 
flow cytometric analysis, a BD LSRFortessa (BD Bioscience, Oxford, UK) 
machine was used. Cell proliferation was calculated using ModFit software 
version 3.2 (Verity Software House, Topsham, ME. USA). The different 
colours used represented different generations of daughter cells that have 
taken up the cell trace dye. A shift to the left indicated proliferation. 
2.16 Statistical analysis 
Data were analysed for statistical significance using analysis of variance 
(ANOVA; and compared columns using Bonferroni), when the graph involves 
multiple comparison or t-test, when data are normally distributed and only 
two sets of data are compared or Mann Whitney U test, when data are not 
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normally distributed and only two sets of data are compared on Graphpad 
prism statistical analysis software (GraphPad Prism 6, GraphPad Software, 
San Diego, CA). ‘n’ represents number of independent experiments. All data 
are expressed as means ± SEM. Values of p< 0.05 were considered 
significant.  *p< 0.05, **p< 0.01, ***p< 0.001, ****p<0.0001. 
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3 IL-22 and IFNλ signalling in human primary 
keratinocytes: Implications for the 
pathogenesis of cutaneous lupus 
erythematosus  
3.1 Introduction 
IL-22 and IFNλ are members of the IL-10 family of cytokines. Well described 
functional effects of IFNλ (STAT1 activation) include: inhibition of proliferation 
and induction of apoptosis (Maher et al., 2008; Regis et al., 2008).  By 
contrast, IL-22 (STAT3 activation) is involved in the following processes: cell 
migration, proliferation, inhibition of differentiation, angiogenesis and 
prevention of fibrosis (Kumar et al., 2013; Muhl et al., 2013). The role of IL-22 
in the pathogenesis of hyperproliferative diseases, such as psoriasis is well 
described (Boniface et al., 2007; Hao, 2014; Sabat et al., 2014) and 
increased production of IL-22 in psoriatic lesion by infiltrating CD4+ T effector 
cells has been reported (Boniface et al., 2007; Wilson et al., 2007). ILC3 
were identified recently as one of the main producers of IL-22 and these cells 
have been implicated in the pathogenesis of psoriasis (Kim, 2015; Villanova 
et al., 2014). Elevated serum levels of IL-22 has been identified as a 
biomarker for psoriasis and a significant decrease in the amount of this 
cytokine, as well as IL-6, paralleled clinical improvement (Cordiali-Fei et al., 
2014; Michalak-Stoma et al., 2013). The high expression of IL-22 in psoriatic 
lesion has been linked with downregulation of genes associated with terminal 
differentiation in keratinocytes, such as involucrin, loricrin and calmodulin. IL-
22 induces the expression of ‘STAT3 signature genes’, including SOCS3 and 
JUNB (Brand et al., 2006). SOCS3 has been described to be highly 
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upregulated in the basal and suprabasal layers of psoriatic skin lesion 
(Federici et al., 2002). SOCS3 in particular has been shown to be involved in 
the inhibition of apoptotic pathway in psoriasis (Bruun et al., 2009; Madonna 
et al., 2012; Tomita et al., 2011) and it acts as negative regulator of the 
JAK/STAT1/3 signalling pathway (Dalpke et al., 2008; Zeitvogel et al., 2012). 
IFNλ induces SOCS1; a negative regulator of the JAK/STAT3 pathway and 
the JAK/STAT1 pathway (Brand et al., 2005). Both in vitro and in vivo 
experiments demonstrated a protective role and damaging effect for STAT3 
and STAT1 respectively (Barry et al., 2007; Stephanou, 2004). The relative 
abundance, activation and cross regulation of STAT1 and STAT3 play crucial 
roles in determining cellular responses to a variety of cytokines and other 
proteins (Hong et al., 2002). STAT1 acts as negative regulator of the 
expression of pro survival genes, such as Bcl-xL and Bcl-2 and has been 
shown to favour apoptosis (Stephanou et al., 2000; Wang et al., 2000). In 
addition, activation of STAT1 by IFNs results in the upregulation of 
proinflammatory genes, including ICAM1, CXCL9 and CXCL10. ICAM1 helps 
with increased leukocytes adhesion to endothelial cell; while CXCL9 and 
CXCL10 act as chemoattractants for cells of hematopoietic origin into the 
tissue (Regis et al., 2008). STAT3 is involved in the induction of anti-
apoptotic genes of the Bcl family (Regis et al., 2008).  Based on the 
possibility for competition for the usage of the shared second receptor, IL-
10R2, and the induction of negative regulators for the JAK/STAT1 pathway, 
SOCS3, it was hypothesised that IL-22 could be a negative regulator of IFNλ 
signalling and activities in human primary keratinocytes; hence, of potential 
therapeutic role in CLE. 
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3.2 Results 
3.2.1 Nucleic acids induce the production of IFNλ protein in human 
primary keratinocytes 
IFNλ plays an important role in the pathogenesis of CLE and it is the main 
IFN produced by keratinocytes. In order to understand how IFNλ is produced 
in keratinocytes, cultured human primary keratinocytes from healthy 
individuals or CLE patients were stimulated with cytokines or nucleic acids for 
48 hours and supernatants were collected for IFNλ1 ELISA. The results 
showed that in both healthy and CLE keratinocytes, only nucleic acids, such 
as poly I:C and  poly dA:dT were able to induce the production of detectable 
IFNλ1 levels (Fig. 3.1A-B). Moreover, the available CLE keratinocytes 
seemed to produce up to 4-fold more IFNλ1 protein than healthy 
keratinocytes (Fig. 3.1B). 
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Figure 3.1: IFNλ1 induction in human primary keratinocytes by nucleic 
acids. 
Cultured primary keratinocytes from healthy individuals or CLE patients were 
either untreated or treated with IFNα, IFNγ, TNFα, poly dA:dT, poly I:C for 48 
hours. Supernatants were collected and concentration of IFNλ1 protein was 
determined by ELISA. (A) Healthy keratinocytes, n=5 (B) CLE keratinocytes, 
n=3. Statistical analysis was done using unpaired t-test. Mean SEM is given; 
*p< 0.05, **p < 0.01. 
A 
B 
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3.2.2 IFNγ enhances the production of IFNλ in human primary 
keratinocytes 
IFNs and TNFα are important molecules in the pathogenesis of CLE. The 
ability of these molecules to enhance IFNλ1 protein induced by poly I:C in 
cultured human primary keratinocytes was investigated. It was known that 
these cytokines do not induce the production of detectable levels of IFNλ1 on 
their own. Healthy or CLE keratinocytes were primed by treating them with 
IFNα, IFNγ or TNFα for 1 hour before adding poly I:C  for 48 hours. The 
result obtained showed that IFNγ significantly upregulated the production of 
IFNλ1 in both healthy and CLE keratinocytes (Fig. 3.2A-B). No enhancing 
effect was observed with IFNα or TNFα in healthy and CLE keratinocytes 
(Fig. 3.2A-B). The enhancing effect of IFNγ was over 2-fold in both healthy 
and CLE keratinocytes as compared to poly I:C alone. However, CLE 
keratinocytes produced about 4-fold more IFNλ1 than healthy keratinocytes 
(Fig. 3.2B). 
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Figure 3.2: IFNγ enhances the production of IFNλ1 in human primary 
keratinocytes.  
Primary keratinocytes from healthy individuals or CLE patients were either 
untreated or treated with IFNα, IFNγ, TNFα, poly I:C alone or a combination 
of cytokine and nucleic acid for 48 hours. Supernatants were collected and 
concentration of IFNλ1 protein was determined by ELISA. For the 
experiments, a minimum of three different donors were used in independent 
experiments. (A) Healthy keratinocytes, n=5 (B) CLE keratinocytes, n=3. 
Statistical analysis was done using unpaired t-test. Values are mean SEM; 
*p< 0.05. 
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3.2.3 IFNλ has autocrine activity in healthy and CLE keratinocytes 
In order to see if IFNλ1 could induce its own expression, keratinocytes were 
stimulated with different concentrations of rhIFNλ1 for 24 hours and gene 
expression was quantified using qRT-PCR. A dose-dependent upregulation 
of IFNλ1 mRNA expression by rhIFNλ1 was observed in both healthy and 
CLE keratinocytes (Fig. 3.3A-B); thus pointing to autocrine activity. Treatment 
of CLE keratinocytes with IFNλ1 did not result in a much higher expression of 
IFNλ1 mRNA in comparison to keratinocytes from healthy individuals. 
 
       
Figure 3.3: IFNλ1 has autocrine effect on its own expression in human 
keratinocytes.  
Primary keratinocytes from healthy individuals or CLE patients were either 
untreated or treated with 10 ng/ml, 100 ng/ml or 200 ng/ml rhIFNλ1 for 24 
hours. IFNλ1 mRNA expression was quantified by qRT-PCR. Relative mRNA 
expression was normalised to U6snRNA and calibrated to untreated control. 
Minimum of 3 independent experiments were carried out using different 
donors (A) n=3 (B) n=5. Mann Whitney U test was used to determine 
statistical significance. Values are mean SEM; *p < 0.05, **p < 0.01, 
***p<0.001.  
A B CLE keratinocytes Healthy keratinocytes 
67 
 
3.2.4 IL-22 counter-regulates the expression of IFNλ-induced CXCL9 
and CXCL10 in healthy primary keratinocytes but not in CLE 
keratinocytes 
It has been shown that pre-treatment of keratinocytes and some cell lines, 
such as DLD1 with IFNα prior to treating with IL-22 resulted in enhanced 
expression of ISGs (Bachmann et al., 2013). In addition, my experiments 
followed the hypothesis that, IL-22 which shares the second receptor with 
IFNλ, could have beneficial effects on IFNλ dominated pathologies, such as 
CLE.  In order to investigate if a relationship exists between IL-22 and IFNλ, 
primary keratinocytes were exposed to IL-22, IFNα, IFNλ1 in different 
combinations and stimulation sequences. IFNα was used as positive control. 
Both healthy and CLE keratinocytes failed to show downregulatory effects to 
IL-22 for any of the ISGs after 6 hours of stimulation (Fig. 3.4A/C/E/G). 
Interestingly, the result showed that the presence of IL-22 was able to 
significantly reduce the expression of IFNλ1-induced CXCL9 and CXCL10 
but not other ISGs investigated in primary keratinocytes from healthy donors 
after 24 hours of treatment (Fig. 3.4B/D/F/H). This downregulatory effect was 
not observed for any ISG in CLE keratinocytes after 24 hours of treatment 
(Fig. 3.5B/D/F/H). Furthermore, it was observed that pre-treating primary 
keratinocytes with IFNα prior to IL-22 stimulation for 6 hours resulted in over 
5-fold and about 2-fold increase in CXCL9 and CXCL10 expression 
respectively in comparison to IFNα treatment alone (Fig. 3.4A/C). This effect 
was lost after 24 hours of treatment. IFNα effect on ISGs expression also 
decreased after 24 hours in Fig. 3.4A-H. Neither the downregulatory effect of 
IL-22 on CXCL9 and CXCL10 expression nor the enhancing effect of IL-22 
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on IFNα-induced expression of CXCL9 and CXCL10 was observable in CLE 
keratinocytes (Fig. 3.4A/C and Fig. 3.5A-D). CLE keratinocytes had higher 
basal expression levels of CXCL9 and CXCL10 in comparison to healthy 
keratinocytes (Fig. 3.4A-D and 3.5A-D).  
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Figure 3.4: Regulation of ISGs expression by IL-22 in healthy 
keratinocytes 
Primary keratinocytes from healthy individuals were either untreated or 
treated with 10 ng/ml IFNα, 100 ng/ml IFNλ1, 100 ng/ml IL-22 alone or with 
IL-22 for 30 minutes before and after addition of IFNs. Cells were treated for 
either 6 or 24 hours. Total RNA was isolated and expression of ISGs was 
quantified by qRT-PCR. (A) CXCL9, 6 hours (B) CXCL9, 24 hours (C) 
CXCL10, 6 hours (D) CXCL10, 24 hours (E) MxA, 6 hours (F) MxA, 24 hours 
(G) GBP-1, 6 hours (H) GBP-1, 24 hours. One-way ANOVA was used to 
determine statistical significance, n=4. Values are mean SEM; *p < 0.05, **p 
< 0.01, ***p < 0.001, ****p < 0.0001.  
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Figure 3.5: Regulation of ISGs expression by IL-22 in CLE keratinocytes 
Primary keratinocytes from CLE patients were either untreated or treated with 
10 ng/ml IFNα, 100 ng/ml IFNλ1, 100 ng/ml IL-22 alone or with IL-22 for 30 
minutes before and after treatment with IFNs. Cells were treated for either 6 
or 24 hours. Total RNA was isolated and expression of ISGs was quantified 
by qRT-PCR. (A) CXCL9, 6 hours (B) CXCL9, 24 hours (C) CXCL10, 6 hours 
(D) CXCL10, 24 hours (E) MxA, 6 hours (F) MxA, 24 hours (G) GBP-1, 6 
hours (H) GBP-1, 24 hours. One-way ANOVA was used to determine 
statistical significance, n=4. Values are mean SEM; *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. 
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3.2.5 IL-22 downregulated CXCL10 production in human primary 
keratinocytes 
Figures above show the downregulatory effect of IL-22 on IFNλ1-induced 
CXCL9 and CXCL10 on the mRNA level in human keratinocytes from healthy 
individual. Additional experiments were performed for the protein level. 
Primary keratinocytes were either untreated or treated with 100 ng/ml IFNλ1 
or pre-treated with different concentrations of IL-22 for 30 minutes before 
adding IFNλ1 for 24 hours. Supernatants were harvested and subjected to 
ELISA assays to determine the amount of CXCL10 secreted. The result 
showed that only higher concentrations of IL-22 (100 and 250 ng/ml) had 
significant downregulatory effect on CXCL10 production by keratinocytes (Fig. 
3.6).  
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Figure 3.6: Dose titration showing effect of IL-22 on IFNλ1-induced 
CXCL10 protein. 
Primary keratinocytes from healthy individuals were either untreated or 
treated with 100 ng/ml IL-22 or 100 ng/ml IFNλ1 or pre-treated with 5 ng/ml, 
50 ng/ml, 100 ng/ml or 250 ng/ml IL-22 for 30 minutes before adding 100 
ng/ml IFNλ1. Cells were treated for 24 hours. Supernatants were collected 
and the amount of secreted CXCL10 was determined by ELISA. Statistical 
significance was determined using unpaired t-test. Values are mean SEM; 
*p < 0.05. 
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3.2.6 CLE keratinocytes showed reduced expression of IL-22R1 in 
comparison to healthy keratinocytes 
Based on the findings above on the regulatory effect of IL-22 on chemokines 
expression and secretion in healthy keratinocytes but not in CLE 
keratinocytes, it was investigated whether this effect could be due to the 
differences in expression levels of IL-22R1 on these cells. Experiments 
performed for the mRNA and protein expression levels showed a significantly 
lower IL-22R1 expression in CLE keratinocytes compared to healthy 
keratinocytes. Healthy keratinocytes on the other hand showed high 
expression of IL-22R1 protein (Fig. 3.7A-C). 
 
 
        
A 
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Figure 3.7: Reduced expression of IL-22R1 in CLE keratinocytes. 
IL-22R1 expression levels were measured in primary keratinocytes from 
healthy or LE patients by qRT-PCR and flow cytometry. (A) Total RNA was 
isolated from cells and IL-22R1 mRNA expression was quantified using qRT-
PCR. Mann Whitney test was used to determine statistical significance; n=4. 
Values are mean SEM; *p < 0.05 (B) Cells were stained with APC-
conjugated anti-human IL-22R1 antibody (blue) and appropriate APC-
conjugated isotype control (red) was used. A representative figure from 3 
independent experiments from 3 donors is shown. 
 
 
 
B C 
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3.2.7 IL-22 induces significant expression of SOCS3 in healthy primary 
keratinocytes 
SOCS1 and SOCS3 are important negative regulators of IL-22 and IFNλ1 
signalling. Like SOCS3, JUNB is also activated downstream of STAT3 and 
has been shown to be an important molecule in psoriatic inflammation. The 
ability of IL-22 and IFNλ1 to induce the expression of these molecules over a 
6-hour period was monitored.  The result showed that IL-22 significantly 
induced the expression of SOCS3 but not SOCS1 and JUNB in primary 
keratinocytes (Fig. 3.8A-D). SOCS3 was induced as early as 30 minutes after 
treatment with peak expression level at 1 hour after treatment with IL-22 and 
returning to about pre-treatment level after 6 hours of treatment (Fig. 3.8A-E). 
IFNλ1 did not induce significant expression of any of the genes investigated 
but showed a tendency for SOCS1 expression (Fig. 3.8A-E). 
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Figure 3.8: Time course induction of SOCS genes by IL-22 and IFNλ1 in 
healthy primary keratinocytes. 
Keratinocytes were either not treated or treated with 100 ng/ml IL-22 or 100 
ng/ml IFNλ1 for time-points ranging between 30 minutes and 6 hours. Cells 
were lysed, RNA extracted and mRNA expression of SOCS3, SOCS1 and 
JUNB was quantified using qRT-PCR. (A) 30 minutes (B) 1 hour (C) 2 hours 
(D) 4 hours (E) 6 hours. Two-way ANOVA was used to determine statistical 
significance; n=3. Values are mean SEM; *p < 0.05, **p < 0.01, ***p<0.001, 
****p<0.0001.  
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3.2.8 IFNλ1 upregulated and downregulated the expression of SOCS1 
and SOCS3 respectively in CLE keratinocytes 
Based on the finding with healthy keratinocytes, expression levels of SOCS 
genes in response to IL-22 and IFNλ1 were investigated in CLE keratinocytes. 
The result showed significant downregulation of SOCS3 by IFNλ1 just after 
30 minutes of treatment (Fig. 3.9A). However, this effect was not observed in 
all the other time points checked (Fig. 3.9B-E). Interestingly, IFNλ1 
significantly upregulated the expression of SOCS1 in CLE keratinocytes after 
2 hours of treatment (Fig. 3.9C). IL-22 failed to show significant effects on the 
expression of the genes investigated (Fig. 3.9A-E). 
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Figure 3.9: Time course induction of SOCS genes by IL-22 and IFNλ1 in 
CLE keratinocytes. 
Cultured CLE keratinocytes were either not treated or treated with 100 ng/ml 
IL-22 or 100 ng/ml IFNλ1 for time-points ranging between 30 minutes and 6 
hours. Cells were lysed, RNA extracted and mRNA expression of SOCS3, 
SOCS1 and JUNB was quantified using qRT-PCR. (A) 30 minutes (B) 1 hour 
(C) 2 hours (D) 4 hours (E) 6 hours. Two-way ANOVA was used to determine 
statistical significance; n=3. Values are mean SEM; *p < 0.05. 
CLE CLE 
CLE CLE 
CLE 
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3.2.9 CLE keratinocytes showed reduced activation of STAT3 upon IL-
22 treatment in comparison to healthy cells 
It is well known that IL-22 induces the phosphorylation of STAT3 in many 
cells, including primary keratinocytes. In order to confirm this and compare 
the levels of phosphorylation in healthy and CLE keratinocytes, cultured cells 
were treated with IL-22 for various time points and cell lysates were analysed 
by western blotting.  The result confirmed the ability of IL-22 to significantly 
induce STAT3 phosphorylation in human primary keratinocytes (Fig. 3.10A-
C). Interestingly, reduced STAT3 phosphorylation was observed in CLE 
keratinocytes in comparison to healthy keratinocytes. This reduced 
phosphorylation in CLE keratinocytes was observed at all the time points 
checked (Fig. 3.10A-D). Most pronounced phosphorylation for both healthy 
and CLE cells was observed 10 minutes after IL-22 stimulation (Fig. 10A-B).  
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Figure 3.10: STAT3 phosphorylation in Healthy and CLE keratinocytes 
by IL-22. 
Keratinocytes from healthy individuals and CLE patients were either 
untreated or treated with 100 ng/ml IL-22 for 10, 30 and 60 minutes. 
Supernatants were removed and cells were lysed, protein quantified by 
Bradford assay and 30 µg of protein was used for Western blotting. (A) 
Representative Western blot figure from 3 independent experiments; (B) 
Percentage band intensity of phospho-STAT3 in healthy versus CLE 
keratinocytes after 10 minutes, 30 min (C), and 60 min (D) of IL-22 treatment;. 
Two-way ANOVA was used to determine statistical significance; n=3. Values 
are mean SEM; *p < 0.05, **p < 0.01, ***p<0.001, ****p<0.0001. UT: 
Untreated. 
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3.2.10 IL-22 and IFNλ1 have contrasting effects on keratinocytes ’gap’ 
closure in scratch assay 
 In order to understand the functional roles of IL-22 and IFNλ1 in repair 
processes, confluent keratinocytes monolayer cultures in 24-well plates were 
scratched to create a clear cell-free area at the centre of the wells. Cells were 
then stimulated with IL-22 or IFNλ1 for 48 hours. IL-22 stimulated cells were 
able to close the scratch area quicker than non-stimulated and IFNλ1 
stimulated cells i.e. 7% and 18% quicker respectively (Fig. 3.11A-B). On the 
contrary, IFNλ1 caused a reduction in the rate of gap closure by up to 10% in 
comparison to the non-stimulated cells (Fig. 3.11A-B). The differential effects 
of IL-22 and IFNλ1 on scratch/gap closure could be seen after 24 and 48 
hours of treatment (Fig. 3.11B). 
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Figure 3.11: IL-22 but not IFNλ1 improves “gap” closure in 
keratinocytes monolayer culture. 
Keratinocytes from healthy donors were allowed to reach about 95% 
confluence in a 24-well plate. The cells were then scratched with p200 
(yellow) pipette tips to create a clear gap across the wells containing the 
monolayer culture. Cells were washed with warm PBS twice in order to 
remove cell debris. Growth medium was replaced and cells were either 
untreated or treated with IL-22 or IFNλ1. Images were taken at 0, 24 and 48 
hours. (A) Analysis of repeat experiments using wimscratch software to show 
percentage of cell covered area (B) Images comparing IL-22 versus IFNλ1 
effects using wimscratch software (Wimasis). Unpaired t-test was used to 
determine statistical significance; n=5. Values represent mean ± SEM, *p < 
0.05. 
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3.2.11 IL-22 improves keratinocytes migration 
Having established the role of IL-22 in improvement of gap closure in human 
primary keratinocytes, further experiments were carried out investigating 
whether this effect was as a result of cell proliferation or migration or both 
and mitomycin C which prevents cell proliferation was used for the 
experimental setup. The results showed that IL-22 improves keratinocytes 
migration in comparison to untreated cells either in the presence or absence 
of EGF. By contrast, IFNλ1 does not have any clear effect on keratinocytes 
migration in comparison to untreated cells (Fig. 3.12A-B). 
 
                
 
 
A 
86 
 
 
   
Figure 3.12: Effect of IL-22 and IFNλ1 on keratinocytes migration. 
Healthy keratinocytes were allowed to reach about 95% confluence in a 24-
well plate. Cells were treated with 5 µg/ml mitomycin C for 2 hours at 37oC. 
The cells were then scratched with p200 (yellow) pipette tips to create a clear 
gap across the wells containing the monolayer culture. Cells were washed 
with warm PBS twice in order to remove cell debris. Growth medium was 
replaced with or without EGF and hydrocortisone and cells were either 
untreated or treated with IL-22 or IFNλ1. Images were taken at 0, 24 and 48 
hours. Images comparing IL-22 vs IFNλ1 effects are shown. (A) Cells 
cultured in full medium (+/+); (B) Cells cultured in medium without 
hydrocortisone and EGF (-/-). 
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3.2.12 STAT3 and STAT1 ‘signature’ genes are upregulated in psoriasis 
and CDLE respectively 
Results from previous experiments showed that CLE keratinocytes are not 
very responsive to IL-22 and that this cytokine downregulated the expression 
of IFNλ1-induced CXCL9 in healthy keratinocytes. Further mRNA expression 
analysis of whole thickness biopsies from lesional skin was carried out using 
qRT-PCR to obtain further information on the potential clinical relevance of 
these findings. The results showed that most of the genes downstream of 
STAT3, such as SOCS3, IL-22, JUNB, hBD2 and IL-22R1 were highly 
upregulated in psoriatic lesion while many genes downstream of STAT1, 
such as MxA, CXCL9, CXCL10, GBP1, IFI16, IFNλ1 and SOCS1 were 
upregulated in both diseases but more pronounced in CDLE lesion (Fig. 
3.13). Interestingly, IL-22BP was upregulated in CDLE lesion but no IL-22 
expression was found in these biopsies. On the contrary, no IL-22BP 
expression was found in psoriatic lesion; paralleled by high IL-22 expression 
(Fig. 3.13).  
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Figure 3.13: Expression of IFN stimulated and STAT3 activated genes in 
human skin biopsies 
4 mm skin biopsies were taken from upper back, active lesions of patients 
with CDLE and psoriasis or healthy control. These biopsies were stored in 
OCT and RNA was isolated in order to measure gene expression of selected 
genes. mRNA expression was measured using qRT-PCR.  Relative 
expression in lesional skin was normalised to U6snRNA (housekeeping gene) 
and calibrated to the healthy control (A) STAT3 activated genes (B) IFN 
stimulated genes. n=5 (2 biopsies for each disease condition and 1 healthy 
donor). Values represent mean ± SEM. 
A 
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3.3 Discussion 
CLE is a complex autoimmune disease which manifests under the influence 
of environmental, immunological and genetic factors. It is well known that UV 
irradiation, different cell types, such as pDCs, cytotoxic T cells and 
keratinocytes, and soluble mediators, such as IFNs play active roles in the 
pathogenesis of CLE. This work is mainly focussed on cytokine regulation 
and/or dysregulation in the skin compartment in the context of inflammatory 
skin diseases. 
A hallmark of LE is immunoreactivity to nucleic acids. Autoantibodies to 
nucleic acids (ANA – antinuclear Ab) are believed to be important in the 
pathogenesis of CLE even in the absence of detectable serum ANA in 
routine laboratory tests. As outlined above, processes (nucleic acid 
immunoreactivity) leading to ANA formation, such as defective clearance of 
apoptotic cells can also lead to production of proinflammatory cytokines, such 
as IFNs. Results of experiments using keratinocytes from both healthy and 
LE patients support the importance of nucleic acids in the initial trigger of skin 
expressed IFNs.TLR3, the main receptor for poly I:C and RIG-I, receptor for 
poly dA:dT have been implicated in the pathogenesis of LE (Hari et al., 2010; 
Wong et al., 2009). It is possible, though not investigated in this project, that 
TLR3 dependent pathway may be involved in the observation that CLE 
keratinocytes show a 4-fold increase in IFNλ1 production in comparison to 
healthy keratinocytes upon nucleic acid stimulation. These receptors may 
already be highly upregulated in LE keratinocytes prior to nucleic acids 
stimulation. IFNs have been implicated in CLE and the ability of IFNα to 
enhance the responsiveness of keratinocytes and other cell types to poly I:C, 
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viral particles or LPS for subsequent production of inflammatory mediators 
has been described (Siren et al., 2005; Tissari et al., 2005). It has been 
suggested that a cross-talk exists between type II and type III IFNs (Li et al., 
2008; Liu et al., 2011). IFNγ has also been shown to upregulate TLR3 and 
MDA5 in smooth muscle cells leading to induction of proinflammatory 
cytokines (Ahmad et al., 2010). The ability of IFNγ to enhance IFNλ1 
production in both healthy and CLE keratinocytes may be due to its 
upregulatory effect on TLR3 expression in keratinocytes and even more so in 
CLE keratinocytes leading to about 4-fold increase in protein production 
(Kajita et al., 2015).  Although IFNγ and IFNα are not ISGs, the autocrine 
effect of IFNλ1 as shown in this study and that of others (Ank et al., 2006) 
suggests that IFNλ1 may be the only IFN which also is an ISG; this may 
allow it to act in a positive feedback loop. The autocrine activity may be of 
relevance in epidermal CLE inflammation. Using immunohistological staining, 
highly upregulated expression of IFNλR1 has been reported in cutaneous 
lesions taken from CLE patients (Zahn et al., 2010). Keratinocytes from CLE 
patients failed to show highly increased IFNλ1 mRNA expression upon IFNλ1 
stimulation in comparison to healthy keratinocytes despite reported high 
expression of IFNλR1 in CLE lesions.  
As outlined above, IL-22 and IFNλ1 are suggested to have opposing 
functions in healing and repair processes. Using reconstituted human 
epidermis, Boniface et al. observed that IL-22 inhibited epidermal 
differentiation but did not induce the expression of Ki-67, a marker for cell 
proliferation (Boniface et al., 2005). This suggests that the mode of action of 
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IL-22 in the skin may be inhibition of differentiation and not active induction of 
hyperproliferation. Contrasting effects of IL-22 and IFNλ1 on scratch closure 
in keratinocytes monolayer culture in vitro were observed. These effects were 
however, modest. Migration and proliferation are two active processes in 
wound healing. The ability of IL-22 to close the scratch on cultured 
keratinocytes monolayer quicker than the non-stimulated control supports the 
role of IL-22 in promoting migration and proliferation in keratinocytes and 
suggests that this cytokine may play an active role in normal wound healing. 
A similar effect of IL-22 on gap closure in keratinocytes monolayer culture in 
vitro has been reported (Eyerich et al., 2009). IFNλ1 on the other hand 
caused delay in gap closure in comparison to untreated control. This 
observation supports the role of IFNλ1 as anti-proliferative agent (Maher et 
al., 2008); suggesting that it may be involved in delayed epidermal healing 
responses. IL-22 and IFNλ1 share the IL-10R2 and in line with some 
predicted competition for ligand binding, the presence of IL-22 in the cell 
culture resulted in significant downregulation of the expression of IFNλ1-
induced CXCL9 and CXCL10 after 24 hours of treatment with the cytokine in 
comparison to IFNλ1 alone. Although this finding is significant, the 
downregulatory effect was not consistently found for other ISGs investigated 
in this work. This may be attributed to slight differences in the transcription 
factors activated upstream of these genes. IFNα has been shown to activate 
ISGF3 upstream of MxA expression while it activates STAT1 homodimer 
upstream of CXCL9 and CXCL10 genes (Ivashkiv and Donlin, 2014; 
Tomasello et al., 2014). The implication of this is that the regulatory role of IL-
22 on IFN signalling may be restricted to the inflammatory/pro-apoptotic/anti-
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proliferative pathway and may not interfere with their antiviral function. This 
assumption is also supported by the fact that the enhancing effect of IL-22 on 
IFNα signalling in keratinocytes was observed for CXCL9 and CXCL10 
expression but not on other ISGs checked (Fig. 3.3A-D; (Bachmann et al., 
2013). A recent report has however shown a synergistic relationship between 
IFNλ2 and IL-22 on the induction of ISGs in rotavirus-infected mouse and 
human intestinal epithelial cell lines through enhanced activation of STAT1 
(Bird, 2015; Hernandez et al., 2015). It is possible that the downregulatory 
effect of IL-22 on IFNλ-induced CXCL9 and CXCL10 expression may not be 
solely due to competition for IL-10R2 but also based on interaction at 
JAK/STAT signalling level. It has been reported that both IL-22 and IFNλ bind 
to their signalling receptors (IL-22R1 and IFNλR1 respectively) with high 
affinity, forming IL-22/IL-22R1 and IFNλ/IL-28R1 binary complex respectively. 
IL-10R2 then recognises and binds to the binary complex to form a ternary 
complex, resulting in full activation of the pathways (Bleicher et al., 2008; Li 
et al., 2004a).  
IL-22 induces SOCS3 in keratinocytes and overexpression of both SOCS3 
and SOCS1 has been shown to downregulate IFNγ-induced expression of 
ICAM-1, MHC class II molecules, CXCL9/10 and CCL2 through the inhibition 
of STAT1 and STAT3 activities (Albanesi et al., 2007; Federici et al., 2002). 
The level of regulation between IFNλ and IL-22 with regards to ISGs 
induction clearly needs further investigation and this work highlights that 
cross-regulation may not simply be due to ligand competition on receptor 
level. A downregulatory effect of IL-22 on IFNλ1-induced CXCL9 and 
93 
 
CXCL10 was not observed after 6 hours of treatment in keratinocytes and 
this may be due to the fact that it takes longer for IFNλ1 to fully activate the 
STAT1 pathway in comparison to IFNα (Maher et al., 2008). It was initially 
unexpected that the presence of IL-22 failed to downregulate IFNλ1-induced 
CXCL9 and CXCL10 expression in CLE keratinocytes. However, as 
observed in this work, this may be well explained by the reduced IL-22R1 
expression on these cells compared to primary keratinocytes from healthy 
donors (Fig. 3.5A-C). The results from this work and that of other have shown 
that IFNα is a quick and strong activator of STAT1 (Bachmann et al., 2013). 
While pre-treatment of healthy keratinocytes with IL-22 prior to IFNα 
treatment for 6 hours showed no significant downregulatory effect on all ISGs 
investigated in comparison to IFNα alone, pre-treatment of keratinocytes with 
IFNα prior to IL-22 treatment for the same period of time surprisingly, 
resulted in upregulation of CXCL9 and CXCL10 expression in comparison to 
IFNα alone. A similar phenomenon has been reported in macrophages. Pre-
treatment of macrophages with either IFNα or IFNγ before treatment with IL-
10 switches the IL-10 activation pattern from predominantly STAT3, which is 
anti-inflammatory, to mainly STAT1, which is pro-inflammatory (Regis et al., 
2008). The report by Bachmann et al. also showed that priming of 
keratinocytes with IFNα switches IL-22 downstream activity from STAT3 
response to STAT1 (Bachmann et al., 2013). The authors argued that this is 
only possible because IFNα effect on STAT1 is strong and quick. A 
seemingly contrary report suggests that IFNα priming of keratinocytes 
upregulates IL-22R1 thereby enhancing IL-22 activity through increased 
activation of STAT3 (Tohyama et al., 2012). The enhancing effect of IL-22 on 
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IFNα-induced CXCL9 expression was however lost after 24 hours of 
treatment and the priming effect was not observed in CLE keratinocytes. The 
inability to observe IL-22 enhancing effect (STAT3 to STAT1 switch) on ISGs 
expression in IFNλ1 primed cells may be due to delayed and not very strong, 
but long lasting STAT1 activation by IFNλ1 (Maher et al., 2008). The ability of 
IL-22 to switch between which STAT pathway to activate is very interesting. 
IL-22 has been shown to protect the liver from immune damage during 
hepatitis infection (Zenewicz et al., 2007) and also protected mice from lung 
epithelial damage (fibrosis) following influenza A virus infection (Paget et al., 
2012). This protective function has been linked to its ability to counteract the 
activities of IFNs and other Th1 associated molecules. IL-22 is important in 
the pathogenesis of psoriasis and increased expression of IL-22 and IL-22R1 
has been reported in active lesions of this disease (Sabat et al., 2014; Wolk 
et al., 2009b). Reduced expression of IL-22R1 in CLE keratinocytes relative 
to that of keratinocytes from healthy individuals is an interesting finding, 
which has not been reported.  IL-22 induces the expression of SOCS3 
through the activation of STAT3 (Brand et al., 2005). The reduced IL-22R1 
expression in CLE keratinocytes may be responsible for reduced activation of 
STAT3 and subsequently reduced expression of SOCS3 upon IL-22 
stimulation. The ability of keratinocytes to induce SOCS3 seems important in 
regulating STAT1 activated chemokines, such as CXCL9 and CXCL10, 
which are important in pathogenesis of CLE. The regulatory role of SOCS3 
on ISGs expression was reported by Zeitvogel et al. for SOCS3 dependent 
downregulated IL-27-induced CXCL10 in human primary keratinocytes 
(Zeitvogel et al., 2012).  
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Gene expression analysis comparing matched biopsies from active lesions 
from CDLE and psoriasis patients showed a distinct pattern of expression. 
The high expression of STAT3 signature genes in psoriatic lesion points to 
the activity of STAT3 activating molecules, such as IL-22 in lesional skin. On 
the other hand, CDLE samples showed high expression of mainly STAT1 
signature genes; suggesting the importance of IFNs in lesion formation. No 
expression of IL-22 was detected in CDLE sample as also recently reported 
(Jabbari et al., 2014) while some IL-22BP was detected. By contrast, high 
expression of IL-22 was detected in psoriatic sample with almost no 
expression of IL-22BP. It has been reported that IL-22BP is often 
downregulated in diseases with elevated levels of IL-22 (Sabat et al., 2014).  
As found in these lesional biopsies, high expression of SOCS3 has also been 
reported before and this has been linked with the sustenance of the AKT 
pathway, which prevents keratinocytes apoptosis (Madonna et al., 2012; 
Mitra et al., 2012b; Takekoshi et al., 2013). Although growth-inhibiting 
functions of SOCS3 have been reported, this molecule undoubtedly plays an 
important role in downregulating inflammatory molecules and reducing 
apoptosis in various mouse models of hepatic inflammation therapy (Jo et al., 
2005).  There seems to be contrasting reports as to the role and expression 
levels of SOCS3 in psoriasis. Contrary to findings in this work and that of 
some others (Madonna et al., 2012; Takekoshi et al., 2013), deficient 
expression of SOCS3 by keratinocytes and T cells from psoriasis patients 
relative to healthy cells has been reported (Eriksen et al., 2010; Sonkoly et al., 
2007). These differences could be as a result of donor-to-donor variation or 
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on the inflammatory “stage” of the disease. Of note, the dynamic of induction 
of SOCS, an immediate early gene, needs to be considered (Fig. 3.8).  The 
downregulation of IL22BP, which is the natural antagonist for IL-22 could be 
of importance in the pathogenic mechanisms in psoriasis. Taken together, 
these results suggest that the IL-22/IL-22R pathway could have potential 
therapeutic importance not only in psoriasis but also in CLE. CXCL9 and 
CXCL10 are key chemokines involved in the pathogenesis of CLE. They are 
involved in the recruitment of CXCR3+ IFNγ-producing T cells, and enhance 
CXCL12-induced pDCs migration to the dermo-epidermal junction 
(Vanbervliet et al., 2003; Wenzel et al., 2005b). As seen in healthy 
keratinocytes, enhancing the ability of IL-22 to downregulate these important 
chemokines in CLE keratinocytes could be beneficial in the treatment of 
CDLE. IFNλ, which is inducible by nucleic acids is the main IFN produced by 
keratinocytes (Zahn et al., 2010). IFNλ in turn induces the expression of ISGs, 
one of which is CXCL9. In order to block the recruitment of pathogenic 
immune cells to the skin and to avoid the priming effect of IFNα and the 
upregulation of IFNλ production by IFNγ thus exacerbating CLE condition, 
early cutaneous administration or upregulation of IL-22 could present an 
approach to prevent lesion progression. However, once this stage is missed, 
administration of IL-22 to CLE lesion could exacerbate the condition rather 
than ameliorate it. IL-22 could also be useful, via SOCS3 induction, to reduce 
excessive apoptosis of keratinocytes as seen in CDLE (Kuhn et al., 2006). To 
properly tackle the problem of scarring in CDLE, it may be essential that an 
appropriate balance is maintained between STAT1 (Th1) and STAT3 (Th17) 
signalling pathways (Jabbari et al., 2014).  It is important to point out that 
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using scratch assay to understanding the roles of IL-22 and IFNλ1 in cell 
monolayer wound in vitro, has its own limitations. Scratching the monolayer 
culture could result in the cells releasing danger signals, such as HMGB1; 
therefore, it is possible that the effects on gap closure seen may not just be 
that of the cytokines of interesting but a combination of many cellular factors. 
The differences in effects of cytokines on gap closure are also usually very 
subtle; hence, the need to repeat experiments several times in order to see 
any appreciable difference between different treatments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: IL-22 INDUCES SOCS3 
EXPRESSION IN HUMAN DERMAL   
FIBROBLASTS THROUGH THE 
PHOSPHORYLATION OF STAT3 
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4 IL-22 induces SOCS3 expression in human 
dermal fibroblasts through the 
phosphorylation of STAT3 
4.1 Introduction 
IL-22 is mainly produced by hematopoietic cells but efficiently stimulates 
tissue cells (Kumar et al., 2013). In the skin, responsiveness to IL-22 was 
thought to be mainly mediated by its action on keratinocytes. The presence 
of IL-22R1 gene and mRNA expression has been reported in human dermal 
fibroblasts but it was suggested that these cells do not respond to IL-22, 
mainly because of the low expression of the receptor in the dermal 
compartment of the skin (Wolk et al., 2009a).  Other groups have also 
reported the presence of this receptor in stromal cells (Nagalakshmi et al., 
2004). However, the responsiveness of stromal/ mesenchymal cells to IL-22 
is a subject of intense research at the moment. It has been reported that 
fibroblasts-like synoviocytes from psoriatic arthritis (PsA) and rheumatoid 
arthritis (RA) patients express IL-22R1 (Mitra et al., 2012a). In addition, 
human synovial fibroblasts from RA patients functionally respond to IL-22 by 
inducing RANKL and MMP9 (Kim et al., 2012). In colonic subepithelial 
myofibroblasts, IL-22 induces the expression of IL-6, IL8, IL-11 and MMPs 
through the activation of the MAPK/NFkB pathway (Andoh et al., 2005). The 
ability of IL-22 to induce the expression of MMPs in different cell types has 
been linked with cancer progression and invasion of surrounding tissue (Wen 
et al., 2014). IL-22 acts in synergy with TGFβ1 to mediate EMT in asthmatic 
airway epithelium (Johnson et al., 2013). So far, the responsiveness of 
dermal fibroblasts to IL-22 has only been shown in mouse dermal fibroblasts, 
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where IL-22 induced the expression of ECM and improved wound healing in 
mice (McGee et al., 2013). 
The aim of this study was to investigate if human dermal fibroblasts are 
sensitive to IL-22 treatment and to see if these cells can contribute to IL-22 
responsiveness of the skin compartment, in particular with regard to 
biological effects involved in tissue repair and healing.  
  
101 
 
4.2 Results 
4.2.1 IL-22R1 is present in human dermal fibroblasts 
The expression of very low levels of IL-22R1 mRNA in human dermal 
fibroblasts has been reported but its functionality has not been fully 
investigated (Wolk et al., 2009a). In order to confirm the expression of IL-
22R1 in fibroblasts and to see if it is regulated, qPCR, Western blotting and 
flow cytometry techniques were used. For qPCR, total RNA was isolated and 
reverse transcribed to cDNA prior to amplification. For Western blotting, cells 
were lysed and the lysate was used to assess IL-22R1 protein expression. 
Primary keratinocytes lysate was used as positive control. For flow cytometry 
analysis, cells were fixed, permeabilised and stained with APC-conjugated 
anti-human IL-22R1 antibody and appropriate isotype control was used. The 
results confirmed both mRNA and protein expression of IL-22R1 in human 
dermal fibroblasts (Fig. 4.1A-D). In Western blotting, major protein bands 
migrating at about 72 kDa were observed; the same size as the band seen in 
keratinocytes lysate used as positive control (Fig. 4.1C). The size of the 
bands was about 9 kDa higher than the predicted molecular weight of IL-
22R1, 63 kDa. 
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Figure 4.1: IL-22R1 is expressed in human dermal fibroblasts. 
Fibroblasts (non-stimulated) were passaged and the presence of IL-22R1 
was verified using qRT-PCR, Western blotting and Flow cytometry. (A) qRT-
PCR quantification and melting peak for U6snRNA and IL-22R1 in non-
stimulated cells; (B) qPCR products for IL-22R1 and the housekeeping gene 
U6snRNA on 2% agarose gel are shown as a representative experiment out 
of three independent experiments; (C) Western blot analysis using 
keratinocytes as positive control; (D) IL-22R1 expression in dermal 
fibroblasts using flow cytometry. Figures are representatives of 3 
independent experiments from 3 donors. KC: Keratinocytes; FB: Fibroblasts. 
IL-22R1   U6 
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4.2.2 IL-22 activated STAT3 pathway in human dermal fibroblasts 
Since IL-22 is capable of activating the STAT3 pathway in many cells types, 
this effect was investigated in human dermal fibroblasts in order to establish 
the responsiveness of these cells to the cytokine. The result showed that IL-
22 is capable of activating the STAT3 pathway in dermal fibroblasts. The best 
effect of IL-22 on STAT3 phosphorylation was observed after 10 minutes of 
treatment and this effect decreased over the time points investigated. The 
activation of the STAT3 pathway was lost completely after 120 minutes of 
fibroblasts treatment with IL-22 (Fig. 4.2). The phosphorylation kinetics is 
similar to what was observed in primary keratinocytes (Fig. 3.10).  
In order to investigate if the activation of STAT3 would result in expression of 
downstream genes, fibroblasts were treated with IL-22 for various duration of 
time. The result showed SOCS3 upregulation in IL-22 treated fibroblasts (Fig. 
4.3A-E). The peak time point for this SOCS3 expression was 1 hour after 
treatment with IL-22 (Fig. 4.3B). The expression level of SOCS3 began to 
drop after 2 hours of treatment with IL-22. IL-22 did not induce significant 
expression of JUNB, which is another gene downstream of STAT3 (Fig. 
4.3A-E). However, there was about 1.5 fold increase in expression of JUNB 
after 1 hour of treatment in comparison to untreated cells (Fig. 4.3B).  
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Figure 4.2: STAT3 is activated in IL-22 treated dermal fibroblasts. 
Fibroblasts were either not treated or treated with 100 ng/ml IL-22 in serum 
free DMEM for 10, 30, 60 or 120 minutes. STAT3 phosphorylation was 
assessed using Western blotting. Results shown are representative of 3 
independent experiments using 3 different donors. 
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Figure 4.3: IL-22 treated dermal fibroblasts express SOCS3. 
Fibroblasts were either not treated or treated with 100 ng/ml IL-22 for time-
points ranging between 30 minutes and 6 hours. mRNA expression of 
SOCS3, SOCS1 and JUNB was quantified using qRT-PCR and results for 
cells exposed to the following stimulation periods are shown: (A) 30 minutes; 
(B) 1 hour; (C) 2 hours; (D) 4 hours; (E) 6 hours. 3 independent experiments 
were carried out using 3 different donors. Two-way ANOVA was used to 
determine statistical significance; n=3. Values are mean SEM; *p < 0.05, **p 
< 0.01, ***p<0.001, ****p<0.0001.  
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4.2.3 IL-22 induced the expression of SOCS3 in a dose-dependent 
manner 
Having observed that IL-22 was able to induce the expression of SOCS3 in 
dermal fibroblasts with the best time point being 1 hour, dose titrations were 
then carried out. The result showed that both 50 and 100 ng/ml IL-22 can 
induce significant expression of SOCS3; however, 100 ng/ml had a more 
significant effect. There was a similar dose-dependent tendency on JUNB 
expression (Fig. 4.4).  
 
                     
Figure 4.4: Dermal fibroblasts respond to IL-22 dose-dependently.  
Fibroblasts were either untreated or treated with different concentration of 
rhIL-22 ranging from 1 ng/ml to 100 ng/ml for 1 hour. SOCS3 and JUNB 
mRNA expression was quantified using qRT-PCR. For statistical analysis, 
two-way ANOVA was used to compare columns. n=3, values represent 
mean± SEM.  *p<0.05, **p<0.01, ***p<0.001. 
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4.2.4 IL-22R1 upregulation resulted in increased SOCS3 expression 
In order to investigate whether receptor upregulated resulted in an enhanced 
functional response to IL-22, dermal fibroblasts were pre-treated with TNFα 
or TGFβ1 prior to IL-22 stimulation. IL-22R1 protein expression was 
measured using flow cytometry while SOCS3 and JUNB mRNA expression 
was measured using qRT-PCR. Treatment of dermal fibroblasts with either 
TNFα or TGFβ1 for 16 hours resulted in increased expression of IL-22R1 
(Fig. 4.5A-B). Interestingly, the result also showed that pre-treatment of 
dermal fibroblasts with either TGFβ1 or TNFα enhanced IL-22-induced 
expression of SOCS3 and JUNB. This increased expression of SOCS3 and 
JUNB was at least 3-fold and 1.5 fold respectively more than in cells that 
were not pre-treated but treated with IL-22 alone (Fig. 4.5C).  
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Figure 4.5: Upregulation of IL22R1 expression leads to increased 
STAT3 signature gene expression. 
Fibroblasts were pre-treated with 5 ng/ml TGFβ1 or 20 ng/ml TNFα for 16 
hours with untreated control. Cells were stained with APC-conjugated IL-
22R1 and appropriate isotype prior to flow cytometric analysis. (A) Untreated 
(blue) and TNFα (green) (B) Untreated (blue) and TGFβ1 (orange) (C) Cells 
pretreated with TGFβ1 or TNFα were washed twice with warm PBS prior to 
stimulation with 100 ng/ml IL-22 for 1 hour. SOCS3 and JUNB mRNA 
expression was quantified using qRT-PCR. Values are mean SEM. n=2. UT: 
Untreated. 
C 
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4.2.5 IL-22 enhanced TGFβ1-induced collagen expression but had no 
effect on CCL2 production 
The ability of IL-22 to induce collagen expression in murine dermal fibroblasts 
has been described (McGee et al., 2013). In order to investigate if IL-22 is 
able to induce the expression of collagens in human dermal fibroblasts, cells 
were treated with IL-22, TGFβ1 or a combination of both. The results showed 
that IL-22 is not able to induce the expression of Col1A1, Col3A1, Col4A2, 
Col7A1 in dermal fibroblasts at the time points investigated (Fig. 4.6A-H). 
TGFβ1, which is known as an inducer of collagen expression, was able to 
induce significant expression of Col1A1 and Col3A1 after 24 hours of 
treatment but not after 6 hours (Fig. 4.6A-D). Interestingly, the results 
showed that IL-22 is able to significantly enhance the expression of TGFβ1-
induced Col1A1, Col4A2 and Col7A1 but not Col3A1 expression after 24 but 
not 6 hours of treatment (Fig. 4.6). Supernatants from IL-22 treated cells 
were used for CCL2 determination. As shown in Figure 4.7, IL-22 did not 
induce significant amount of CCL2 protein relative to the untreated control. 
The result also showed that dermal fibroblasts produce high CCL2 levels 
constitutively (Fig. 4.7).  
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Figure 4.6: Effect of IL-22 on collagen expression in dermal fibroblasts 
Fibroblasts were treated with 100 ng/ml IL-22 or 5 ng/ml TGFβ1 or 
combination of IL-22 and TGFβ1 for 6 or 24 hours in serum free medium. 
mRNA expression of collagens was measured by qRT-PCR. (A) Col1A1 
expression after 6 hours; (B) Col1A1 expression after 24 hours; (C) Col3A1 
expression after 6 hours; (D) Col3A1 expression after 24 hours; (E) Col4A2 
expression after 6 hours; (F) Col4A2 expression after 24 hours; (G) Col7A1 
expression after 6 hours (H) Col7A1 expression after 24 hours. For statistical 
analysis, one-way ANOVA was used to compare columns. n=4, values 
represent mean± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Figure 4.7: Effect of IL-22 on CCL2 production in dermal fibroblasts. 
Cultured dermal fibroblasts were either untreated or treated with 100 ng/ml 
IL-22 for 24 hours. Supernatants were collected and the amount of secreted 
CCL2 in culture supernatant was determined using ELISA. n=4, values 
represent mean± SEM.   
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4.2.6 IL-22 does not induce fibroblasts proliferation and does not affect 
‘scratch’ gap closure 
In order to investigate whether IL-22 is able to induce fibroblasts proliferation, 
human dermal fibroblasts were stained with cell tracer dye and were treated 
with IL-22 for 72 hours. The results showed that IL-22 does not induce any 
detectable level of proliferation in dermal fibroblasts (Fig. 4.8A-B). The effect 
of IL-22 on cell monolayer gap closure was also investigated by treating 
dermal fibroblasts with IL-22 for 48 hours. The results showed that IL-22 
does not affect ‘scratch’ closure in these monolayer cultures (Fig. 4.9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
  
 
 
 
 
Figure 4.8: Effects of IL-22 on proliferation of dermal fibroblasts 
Human dermal fibroblasts were labelled with cell trace violet. Cells were 
treated with IL-22 (100 ng/ml) for 72 h. Proliferation as a measure of 
fluorescence signal was determined by flow cytometric analysis. (A) As the 
cells divide, the cell trace violet is diluted between daughter cells causing a 
shift in fluorescence peak towards the left side. The histogram of daughter 
cells populations is depicted; (B) Graphical representation of percentage cell 
proliferation; n=3, values represent mean± SEM.   
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Figure 4.9: IL-22 does not enhance a ‘scratch’ gap closure in fibroblast 
monolayers.  
Monolayer culture of human dermal fibroblasts was allowed to grow to 95% 
confluency and scratched with p200 (yellow) pipette tip. Cells were either 
untreated or treated with IL-22 for 48 hours in DMEM without serum. Images 
were taken at 0, 24 and 48 hours with Nikon camera under x4 objective. 
Images are representatives of 2 independent experiments using 2 different 
donors. No obvious acceleration in gap closure in IL-22 compared to non-
treated cells was observed.  
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4.3 Discussion 
As outlined above, IL-22 has been shown to play important role in cell 
migration, cell proliferation, prevention of tissues damage and angiogenesis 
(Lim and Savan, 2014; Ren et al., 2010; Zenewicz et al., 2007) particularly in 
epithelial compartments. IL-22R1 determines cellular responsiveness and its 
expression is restricted to tissue cells and not cells of hematopoietic origin 
(Lim and Savan, 2014). Very low levels of IL-22R1 mRNA expression has 
been reported in human dermal fibroblasts; however, the responsiveness of 
these cells to IL-22 treatment has not been established (Wolk et al., 2009a). 
Protein data showing the presence of IL-22R1 in human dermal fibroblasts 
has also not been reported. IL-22R1 has been described in mouse dermal 
fibroblasts and these cells have shown responsiveness to IL-22 stimulation 
resulting in STAT3 activation, myofibroblasts differentiation and extracellular 
matrix production (McGee et al., 2013). It is thus a major finding of this 
project that IL-22R1 mRNA and protein are expressed in untreated human 
dermal fibroblasts. The predicted molecular weight of IL-22R1 is 63kDa; 
however, the IL-22R1 protein band was observed at 72kDa on the PVDF 
membrane, the same size as observed in human primary keratinocytes. The 
9kDa difference in predicted molecular weight and the actual size seen in 
Western blotting may be attributed to glycosylation of IL-22R1 at three 
putative N-linked glycosylation (Asn-X-Thr) sites in the extracellular domain of 
the receptor (Sabat et al., 2014). It is interesting that the expression of IL-
22R1 in dermal fibroblasts is regulated by TGFβ1 and TNFα, which are 
generally regarded as anti-inflammatory and proinflammatory cytokines, 
respectively. Increased expression of IL-22R1 in the presence of TNFα has 
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been reported in fibroblasts-like synoviocytes (FLSs) from patients suffering 
from RA and osteoarthritis (OA) (Carrion et al., 2013). It is well known that IL-
22 exerts its biological effect on cells through the activation of mainly STAT3 
(Sabat et al., 2014; Wolk et al., 2004). The above results confirm that IL-22 
activates this signalling pathway also in human dermal fibroblasts, which has 
not been shown before. The induction of SOCS3 expression by dermal 
fibroblasts following IL-22 treatment suggests that these cells may contribute 
to high expression of SOCS3 seen in skin lesion of patients with active 
psoriasis (Fig. 3.14; (Takekoshi et al., 2013)) and it is interesting that TNFα – 
known to be involved for psoriasis plaque formation -  could enhance this 
effect. The role of TNFα in lupus is controversial. Our group has previously 
shown that this cytokine may be important in counteracting the damaging 
effect of IFNs on skin cells (Alase, 2013). By positively regulating SOCS3 
expression in dermal fibroblasts, TNFα may enhance the beneficial effect of 
IL-22 in reducing apoptosis in CLE skin. Although IL-22 treatment alone did 
not have any effect on collagen expression in dermal fibroblasts, this cytokine 
enhanced TGFβ1-induced collagen types I, IV and VII expression. This 
finding suggests a positive role for IL-22 in basement membrane formation 
and maintenance of skin integrity. The enhancing effect of IL-22 on TGFβ1-
induced EMT in asthmatic bronchial epithelial cells has previously been 
reported (Johnson et al., 2013). The importance of IL-22 in cell proliferation 
has been identified by many groups (Brand et al., 2006; Carrion et al., 2013). 
However, some have suggested that the IL-22 effect is limited to inhibition of 
expression of markers for terminal differentiation in cells and that it does not 
actively drive cell proliferation (Boniface et al., 2005). As also seen in primary 
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keratinocytes, IL-22 did not significantly induce proliferation in dermal 
fibroblast. The differences between the findings in this work and that of Brand 
et al. and Carrion et al. regarding the role of IL-22 on cells proliferation may 
be explained by the fact that these two groups measured cells proliferation 
using MTS assay, a technique that determines metabolic activities of the 
cells rather than true proliferation (i.e higher metabolic activity not always 
equals increased proliferation). IL-22 also failed to induce proliferation in 
colonic subepithelial myofibroblasts (Andoh et al., 2005). While IL-22 
improved the rate of ‘scratch gap’ closure in primary keratinocytes ((Scarponi 
et al., 2014); Fig. 3.11A-B), no significant effect on gap closure was observed 
in dermal fibroblasts. This finding is contrary to what was observed in mouse 
dermal fibroblasts, where IL-22 improved wound healing (McGee et al., 2013). 
The ability of IL-22 to induce the expression of CCL2 in epithelial cells and 
hepatocytes has been reported (Donnelly et al., 2004; Scarponi et al., 2014). 
IL-22 failed to induce significant amount of CCL2 protein in dermal fibroblasts. 
This finding suggests that the dermal compartment may not be involved in IL-
22 induced recruitment of leukocytes and monocytic infiltrates into the skin 
during skin inflammation in diseases, such as psoriasis. 
Taken together, these findings suggest that human dermal fibroblasts may 
play an important role in inflammatory conditions with high expression of IL-
22. IL-22 may support healing responses in synergy with TGFβ. The lack of 
chemokine production may well be in line with the rather inflammation 
“limiting” role of the dermal as compared to the epidermal compartment as 
hypothesised by our group (Wittmann et al., 2012). Thus, IL-22 could play a 
beneficial role in CLE by inducing anti-apoptotic pathways and sustaining cell 
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survival through active induction of SOCS3 expression. These functional 
responses have not been addressed in this work and it would be of high 
interest to gain further insight in the disease specific impact of IL-22 on the 
dermal compartment (e.g. in CLE and psoriasis). However, results presented 
here contribute to the growing evidence of involvement of IL-22 in wound 
healing and maintenance of skin integrity through enhanced collagen 
deposition. In addition, this study further highlights that dermal fibroblasts are 
not just connective tissue cells but are active players in the overall skin 
immunology.                                                                     
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CHAPTER 5: IFNλ STIMULATES MXA 
PRODUCTION IN HUMAN DERMAL 
FIBROBLASTS VIA A MAPK-DEPENDENT 
STAT1-INDEPENDENT MECHANISM 
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5 IFNλ stimulates MxA production in human 
dermal fibroblasts via a MAPK-dependent 
STAT1-independent mechanism 
5.1 Introduction   
Fibroblasts and keratinocytes are the main tissue cell types found in the 
dermis and epidermis respectively. While many recent studies have identified 
the immunological role of keratinocytes, the role of dermal fibroblasts in host 
defence and inflammatory diseases are only beginning to emerge. 
Furthermore, dermal fibroblasts synthesise extracellular matrix including 
collagens (Xu et al., 2009) and thus play an important role in maintaining skin 
structure and promoting repair and healing responses. Although IFNλ is 
structurally related to IL-10, it resembles type I IFNs in its antiviral and anti-
proliferative functions (Miknis et al., 2010). They both signal mainly through 
the recruitment and activation of members of the Janus family of kinases, 
JAK1/TYK2 leading to the phosphorylation of signal transducer and activator 
of transcription (STAT) 1/2 and subsequently to induction of a set of 
downstream genes known as IFN-stimulated genes (ISGs), coding for 
proteins, such as Myxovirus protein A (MxA), Guanylate binding protein 1 
(GBP-1), 2,5-oligoadenylate synthetase (2,5-OAS) and IFN inducible protein 
16 (IFI16) with potent antiviral activities (Ank et al., 2008; Sommereyns et al., 
2008). Beyond JAK/STAT activation, type I IFNs have also been found to 
activate MAPK (p38 and ERK (p42/p44) MAPK) which allows for full 
activation of downstream ISGs (Nguyen et al., 2000; Uddin et al., 2000); and 
possibly downstream phosphorylation of STAT1 on serine 727 (Goh et al., 
1999). 
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Type I IFNs signal through membrane associated IFNAR1 and IFNAR2 
(Lutfalla et al., 1995). While the two subunits of IFNAR are present on all 
nucleated cell types, IFNλR1 is selectively expressed and functional in 
certain cell types only (Dickensheets et al., 2013; Kotenko et al., 2003; Witte 
et al., 2009; Zahn et al., 2010). Witte et al. described the presence of IL-
28Rα1 mRNA expression in human dermal fibroblasts. However, it was 
observed that these cells were unresponsive to IFNλ, and this was attributed 
to the very low expression level of the receptor in these cells (Lasfar et al., 
2011; Witte et al., 2009).  
IFNλ is the main IFN produced by keratinocytes and production of varying 
amounts of this cytokine has been reported also in other cell types (Wolk et 
al., 2013; Yin et al., 2012; Zahn et al., 2010). Keratinocytes are susceptible to 
IFNλ1 and this cytokine substantially contributes to the antiviral competence 
of the human epidermis (Wolk et al., 2013). Apart from antiviral properties, 
both types I and III IFNs are known for their pro-apoptotic and anti-
proliferative activities (Abushahba et al., 2010; Steen and Gamero, 2010); 
which has also been reported for HaCaT keratinocyte cell lines (Maher et al., 
2008). These activities have been linked to the ability of IFNs to 
phosphorylate STAT1 (Zitzmann et al., 2006). High expression of ISGs, such 
as CXCL9, CXCL10, MxA and GBP-1 has been reported in interface 
dermatitis conditions, such as CLE and here increased expression is linked 
with disease severity (Naschberger et al., 2010; Wenzel et al., 2005a).  
The aim of this study was to understand if human dermal fibroblasts are 
responsive to IFNλ1 through the activation of STAT1 and subsequent 
downstream induction of ISGs. There was also need to understand the role 
123 
 
of this cytokine in maintenance of skin integrity with regard to collagen 
expression and proliferation of skin resident cells. 
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5.2 Results 
5.2.1 IFNλR1 is expressed by human dermal fibroblasts 
The presence of low levels of IFNλR1 mRNA in human dermal fibroblasts 
has been reported (Witte et al., 2009). In order to confirm the expression of 
IFNλR1 in fibroblasts mRNA expression was measured by qRT-PCR and 
protein expression was measured by Western blotting and flow cytometry. 
The result showed that IFNλR1 is expressed in dermal fibroblasts and it is 
upregulated in the presence of IFNα (Fig. 5.1A-F).  
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Figure 5.1: IFNλR1 expression and production in human dermal 
fibroblasts 
Human dermal fibroblasts were either untreated or treated with 10 ng/ml 
IFNα for 4 or 16 hours in serum-free medium for mRNA and protein 
expression respectively. (A) Amplification and melting peak showing IFNλR1 
and U6snRNA; (B) qPCR products for IFNλR1 and the housekeeping gene 
U6snRNA on 2% agarose gel are shown as a representative experiment out 
of five independent experiments. (C) Relative mRNA expression is shown for 
five independent experiments. (D) A representative Western blot result for 
IFNλR1 protein and (E) protein band intensity analysis are depicted; n=3. (F) 
A representative (n=3) histogram of flow cytometry analysis depicting the 
staining intensity for the IFNλR1 and appropriate isotype control. For 
statistical analysis, Mann Whitney U test was used. Values represent mean ± 
SEM.  *p<0.005, **p<0.01. UT: Untreated; K: keratinocytes. 
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5.2.2 IFNλ induces significant expression of MxA in human dermal 
fibroblasts 
To investigate if IFNλR1 is functional in human dermal fibroblasts, cells were 
treated with rhIFNλ or rhIFNα (positive control). mRNA expression of ISGs 
was quantified using qRT-PCR. The result showed significant expression of 
MxA but not GBP-1 and OAS2 after 4 and 24 hours of IFNλ1 treatment (Fig. 
5.2A-F). As expected, when compared to IFNλ1, IFNα induced significantly 
higher expression of MxA and GBP-1 after 4 hours of treatment. However, 
while the expression of MxA and OAS2 remained high after 24 hours of 
treatment with IFNα, GBP-1 expression dropped significantly over this time 
period (Fig. 5.2B/D/F). In fibroblasts, IFNα appeared to induce higher 
upregulation of MxA as compared to OAS2 and GBP-1 (Fig. 5.2A-F).  
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Figure 5.2: Interferon stimulated genes (ISGs) expression in human 
dermal fibroblasts 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml 
IFNα or 100 ng/ml IFNλ1 for 4 or 24 hours in serum-free medium. mRNA 
expression of ISGs was measured using qRT-PCR. (A) MxA, 4 hours; (B) 
MxA, 24 hours; (C) GBP-1, 4 hours; (D) GBP-1, 24 hours; (E) OAS2, 4 hours; 
(F) OAS2, 24 hours. For statistical analysis, Mann Whitney U test was used. 
n=5, values represent mean ± SEM.  *p<0.05, **p<0.01. 
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5.2.3 IFNα and IFNλ induce ISG expression in human primary 
keratinocytes 
The findings on ISGs expression in fibroblasts was compared with the 
expression pattern in human primary keratinocytes. The responsiveness of 
keratinocytes to both type I and III IFNs is well documented (Bachmann et al., 
2013; Zahn et al., 2011; Zahn et al., 2010). The result showed that both IFNα 
and IFNλ1 induced significant mRNA expression of MxA, OAS2 and GBP-1 
with a higher induction of MxA as compared to OAS2 and GBP-1 (Fig. 5.3A-
F). Interestingly, a different time kinetic was observed for the ISG response to 
IFNα as compared to IFNλ1. IFNα showed a stronger upregulation of MxA, 
OAS2 and GBP-1 at 6 hours in comparison to IFNλ1, while IFNλ1 stimulation 
resulted in a strong increase in MxA, OAS2 and GBP-1 expression between 
6 and 24 hours. This suggests that IFNλ1 stimulation may result in more 
delayed and/or longer lasting effects (Fig. 5.3A-F) as previously observed in 
hepatocytes (Bolen et al., 2014).  
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Figure 5.3: Interferon stimulated genes (ISGs) expression in human 
primary keratinocytes. 
Human primary keratinocytes were either untreated or treated with 10 ng/ml 
IFNα or 100 ng/ml IFNλ1 for 6 or 24 hours in KGM (-/-). mRNA expression of 
ISGs was measured using qRT-PCR. (A) MxA, 4 hours; (B) MxA, 24 hours; 
(C) GBP-1, 4 hours; (D) GBP-1, 24 hours; (E) OAS2, 4 hours; (F) OAS2, 24 
hours. For statistical analysis, Mann Whitney U test was used. n=5, values 
represent mean ± SEM.  *p<0.05, **p<0.01. 
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5.2.4 IFNλ activates p38 and ERK MAPKs but not STAT1 (Tyr701) in 
human dermal fibroblasts 
Type I and III IFNs are known to activate the canonical JAK/STAT pathway to 
induce downstream gene expression. Having established that dermal 
fibroblasts respond to IFNλ1, the mechanism of action of this cytokine was 
then investigated. To achieve this, dermal fibroblasts were treated with either 
IFNλ1 or IFNα for different time periods and protein phosphorylation was 
determined using western blotting. As expected, IFNα-induced STAT1 
phosphorylation with maximal phosphorylation detected after 30 minutes of 
stimulation (Fig. 5.4A). However, no STAT1 phosphorylation in IFNλ1 treated 
cells was observed in any of the time points investigated. Various groups 
have reported that phosphorylation of p38 may be necessary for full 
activation of STAT1 dependent genes (Goh et al., 1999; Platanias, 2003; 
Uddin et al., 2000). Therefore, the ability of IFNλ1 to induce the 
phosphorylation of p38 in dermal fibroblasts was investigated and we clearly 
found activation of this MAPK (Fig. 5.4A). IFNα treatment resulted in p38 
phosphorylation in addition to STAT1 phosphorylation (Fig. 5.4A). 
Furthermore, both IFNα and IFNλ1 induced phosphorylation of ERK pathway 
in dermal fibroblasts. As expected, both IFNα and IFNλ1 induced STAT1 
phosphorylation in human primary keratinocytes (Fig. 5.4B). However, no 
clear IFNλ dependent activation of either the p38 or ERK pathway upon 
treatment with IFNs was observed (Fig. 5.4B). 
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Figure 5.4: IFNλ1 induced STAT1 and MAPKs phosphorylation 
fibroblasts and keratinocytes 
Human dermal fibroblasts (5.4A) or primary keratinocytes (5.4B) were either 
non treated or treated with 10 ng/ml IFNα or 100 ng/ml IFNλ1 for 10, 30 or 60 
minutes. Total and phosphorylated p38, ERK and STAT1 along with GAPDH 
were detected by Western Blot.  A representative out of three independent 
experiments is depicted. UT: untreated. 
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5.2.5 P38 and ERK inhibitors attenuate IFNλ1-induced MxA protein 
expression  
Based on the finding that IFNλ1 induces the activation of the p38 and ERK 
MAPKs, there was need to understand if these were responsible for the 
induction of MxA expression in dermal fibroblasts. To investigate this, 
fibroblasts were pretreated with p38 (10 μM SB203580) or ERK inhibitor (30 
μM PD98059 or 10 μM U0126) for 1 hour before treatment with IFNλ1 or 
IFNα and analysis of mRNA or protein expression. Interestingly, the results 
showed that the expression of MxA was not regulated at the mRNA level by 
the MAPK inhibitors, as no significant difference in MxA mRNA expression in 
their presence or absence upon stimulation with cytokines was observed (Fig. 
5.5A-B). However, at the protein level, the presence of either the p38 or ERK 
inhibitor abrogated IFNλ1 induced MxA protein production (Fig. 5.5C). No 
decrease in IFNα induced MxA protein production in fibroblasts in the 
presence of SB203580, PD98059 or U0126 was observed (Fig. 5.5D). It was 
also investigated whether MAPKs played a role in IFNλ1-induced MxA 
protein expression in human primary keratinocytes. When these cells were 
treated in the same manner as the fibroblasts, no significant effect on IFNλ1 
and IFNα induced MxA protein production in the context of p38 or ERK 
inhibition was observed (Fig. 5.5E). 
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Figure 5.5: Inhibition of MxA production by p38 and ERK inhibitors 
Dermal fibroblasts or primary keratinocytes were either untreated or treated 
with MAPK inhibitors or IFNs for 4 and 24 hours and MxA was detected on 
the mRNA level and by Western blot (24 hours). (A) MxA mRNA expression, 
4 hours; n=3; (B) MxA mRNA expression, 24 hours; n=3; (C) MxA protein 
expression by IFNλ1 in the presence or absence of MAPK inhibitors in 
fibroblasts; (D) MxA protein expression by IFNα in the presence or absence 
of MAPK inhibitors in fibroblasts; (E) MxA protein expression by IFNλ1 and 
IFNα in human primary keratinocytes in the presence or absence of MAPK 
inhibitors. Figures are representative of three independent experiments. SB: 
SB203580 (p38 inhibitor); U: U0126 (MEK/ERK inhibitors).  
 
 
 
 
 
 
E 
136 
 
5.2.6 IFNλ enhances collagen expression in TGFβ1-treated human 
dermal fibroblasts  
Dermal fibroblasts are essential for extracellular dermal matrix (ECM) 
homeostasis and also contribute to basement membrane formation and thus 
play an important role in repair processes. As conditions with high type I IFN 
expression can be linked to impaired healing responses, it was investigated 
whether IFNλ1 had any influence on collagen expression. Fibroblasts were 
treated with IFNλ1, IFNα, TGFβ1 or a combination of IFN and TGFβ1 for 24 
hours. TGFβ1 was used as a control, given its well described stimulation of 
fibroblast proliferation and collagen synthesis. Col1A1, Col3A1, Col4A2 and 
Col7A1 expression was measured using qRT-PCR. TGFβ1 significantly 
induced the expression of these collagens. Combined treatment of cells with 
IFNλ1 and TGFβ1 resulted in a significantly higher expression of these 
collagens (except for Col3A1) than with either treatment alone (Fig. 5.6A-D).  
 
 
 
 
 
 
 
 
137 
 
 
 
 
 
Figure 5.6: Effect of IFNλ of collagen expression in human dermal 
fibroblasts. 
Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml 
IFNα, 100 ng/ml IFNλ1, 5 ng/ml TGFβ1 or combination of IFNλ1 and TGFβ1 
for 24 hours. mRNA expression of ISGs was measured using qRT-PCR. 
Depicted is Col1A1 (a) Col3A1 (b) Col4A2 (c) and Col7A1 (d) expression. For 
statistical analysis, one-way ANOVA was used. n=5, values represent mean± 
SEM; *p<0.005, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.2.7 IFNλ has potent anti-proliferative activity in primary keratinocytes 
but not in dermal fibroblasts  
The anti-proliferative effect of IFNλ1 on HaCaT keratinocyte cell lines has 
been described (Maher et al., 2008). It was therefore important to compare 
the effect of both IFNλ1 and IFNα on primary skin cells. Cultured human 
primary keratinocytes and dermal fibroblasts were stained with cell tracer dye 
and subsequently stimulated with either IFNλ or IFNα for 72 hours. As 
expected, both IFNs clearly reduced keratinocyte proliferation (Fig. 5.7A-B). 
By contrast, we observed that IFNα but not IFNλ1 inhibits dermal fibroblast 
proliferation (Fig. 5.7C-D). TGFβ1, known to induce fibroblast proliferation, 
was used as positive control (Fig. 5.7C-D).  
The effects of IFNλ1 and IFNα on “gap” closure in monolayer cultures of 
dermal fibroblasts to which both migration and proliferation of cells contribute 
was investigated. Confluent fibroblast cultures were “scratched” and 
stimulated with IFNs. Gap closure was monitored at time 0, 24 and 48 hours. 
The result showed that IFNλ1 even improved gap closure in fibroblasts while 
IFNα delayed gap closure after 48 hours of stimulation in comparison to the 
untreated cells (Fig. 5.8).  
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Figure 5.7: Effects of IFNs on proliferation of skin resident cells 
Human dermal fibroblasts or primary keratinocytes were labelled with cell 
tracer violet in DMEM containing 1% FBS and KGM respectively. Plated cells 
were either untreated or treated with cytokines. Daughter cell populations 
(highlighted by different colours) of dividing cells were visualised by flow 
cytometric analysis after 72 hours of stimulation. Division leads to decrease 
in fluorescence and thus increased proliferation results in an increase of 
daughter cell populations on the left end of the histogram. (A) Cell tracer 
dependent fluorescent signal in keratinocytes at 0 hour and after exposure to 
IFNλ1/IFNα/medium alone for 72 hours is depicted in histograms. (B) 
Percentage proliferation of keratinocytes after 72 hours is shown (n=3). (C) 
Histograms for cell tracer dependent fluorescent signal in fibroblasts at day 0 
and 72 hours after stimulation with TGFβ/IFNλ1/IFNα/medium. (D) 
Percentage proliferation of fibroblasts after 72 hours is shown (n=3). For 
statistical analysis, unpaired t test was used; n=3; values represent mean± 
SEM.  *p<0.05, **p<0.01. 
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Figure 5.8: Differential effects of IFNλ1 and IFNα on dermal fibroblasts 
monolayer culture gap closure. 
Monolayer culture of human dermal fibroblasts in 24-well plate was allowed 
to grow to 95% confluence and scratched with p200 (yellow) pipette tip. Cells 
were either untreated or treated with IFNλ1 or IFNα for 48 hours in DMEM 
without serum Images were taken at 0, 24 and 48 hours with Nikon camera 
under x4 objective. Graphical representation of three independent 
experiments using three different donors. n=3; values represent mean ± SEM. 
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5.3 Discussion 
Types I and III innate IFNs were initially identified for their potent antiviral 
activities (MacMicking, 2012; Sadler and Williams, 2008). IFNs can regulate 
around 2000 different genes (Hertzog et al., 2011) and among the ISGs, MX1, 
which encodes for MxA, is highly inducible and one of the most potent anti-
viral factors which has been shown to block the early replication events of 
different RNA and DNA viruses (Sadler and Williams, 2008). In addition, IFNs 
also have immunoregulatory, anti-proliferative and pro-apoptotic properties; 
they have been identified as potential anticancer drugs (Abushahba et al., 
2010; Witte et al., 2010). They are also important mediators in the 
pathogenesis of autoimmune diseases, such as CLE (Meyer, 2009; 
Ronnblom and Eloranta, 2013). 
Type III IFN is the most recently described group of IFNs. Expression of their 
specific receptor was thought to be restricted mainly to epithelial cells 
(keratinocytes) and hepatocytes. There is, however, emerging evidence that 
IFNλR1 is also present and functional on hematopoietic cells, such as pDCs, 
monocyte-derived macrophages, and T cells (Dai et al., 2009; Liu et al., 2011; 
Mennechet and Uze, 2006; Yin et al., 2012). Apart from the canonical 
JAK/STAT pathway for IFN signalling, there are reports identifying MAPKs as 
regulators of IFN downstream activities (Gough et al., 2008; Uddin et al., 
2000; van Boxel-Dezaire et al., 2006). The contribution and significance of 
different (non JAK) kinases activated in response to IFNs has been 
speculated before to contribute to cell-type and IFN subtype specific 
responses (van Boxel-Dezaire et al., 2006). However, so far, only few studies 
show data of IFNλ induced signalling in primary skin cells. This work is novel 
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because it shows a distinct signalling and thus also functional response of 
primary human fibroblasts to IFNλ which is different from the response of 
these cells to type I IFN and which is clearly different from the response of 
epidermal cells. Indeed, keratinocytes show a similar signalling and 
functional response to both type I and type III IFNs, which is characterised by 
a STAT1 dependent upregulation of a broad range of ISGs. Dermal 
fibroblasts have been considered to be unresponsive to this IFNλ 
(Abushahba et al., 2010). The results presented here challenge this 
previously held view by showing that human fibroblasts respond to IFNλ1 
treatment with significant expression of MxA mRNA and protein. In line with 
findings in this work, a recent study has reported the responsiveness of CMV 
infected foreskin fibroblast to IFNλ3 (Egli et al., 2014). It is well documented 
that types I and III IFNs induce similar sets of ISGs in many cell types (Ank et 
al., 2008; Sommereyns et al., 2008). However, in fibroblasts, significant 
expression of GBP-1 or OAS2 upon IFNλ1 treatment was not observed (Fig. 
5.2D/F). The inability of IFNλ1 to activate STAT1 (Tyr701) in fibroblasts was 
unexpected as this is the known canonical pathway for the induction of 
downstream ISG genes. However, the findings in this work on IFNλ1-induced 
activation of both p38 and ERK suggest that the MAPK pathway may be an 
alternative for the induction of MxA by IFNλ in fibroblasts. It has been 
suggested that IFNα-induced phosphorylation of MAPKs and STAT1 are 
independent of each other; however, they work in tandem to ensure full 
activation of ISGs (Li et al., 2004b). It is interesting that despite these findings, 
inhibition of p38 and ERK in IFNα treated dermal fibroblasts did not result in 
significant downregulation of MxA protein expression; although a slight 
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reduction in MxA production by primary keratinocytes was observed following 
inhibition of ERK but not p38. A more recent report has shown that both 
IFNλ1 and IFNα induce the activation of PI3K-AKT and Raf-MEK-ERK 
pathways in HepG2.2.15 cell lines (Chai et al., 2011). With regard to skin 
tissue cells i.e. keratinocytes and fibroblasts, no activation of the AKT 
pathway was observed.  A proposed mechanism of IFNα and IFNλ1 
signalling in dermal fibroblasts is shown in Figure 5.9 
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Figure 5.9: Proposed schematics of IFNα and IFNλ1 signalling in human 
dermal fibroblasts 
Upon stimulation of fibroblasts with IFNα, there is mainly the phosphorylation 
of STAT1 and to a lesser extent MAPKs (p38 and ERK). This results in the 
production of MxA and other ISGs. Blocking the MAPKs pathways, may lead 
to slight reduction in MxA production and possibly for other ISGs too. By 
contrast, stimulation of fibroblasts with IFNλ results in phosphorylation of 
mainly the MAPKs pathway with no phosphorylation of STAT1. The 
phosphorylation of p38 and ERK leads to significant production of MxA but 
not the other ISGs. Blocking these MAPKs pathways results in attenuation of 
MxA production. 
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It was indeed surprising that no significant regulatory effects of the MAPK 
inhibitors was observed at the transcriptional level, suggesting that p38 and 
ERK inhibition result in posttranscriptional regulation of MxA. Mechanisms of 
mRNA translation of ISGs have been reviewed (Joshi et al., 2010). Both the 
p38 and p42/44 MAPKs can control the activation of eIF4E and other 
substrates of MAPK interacting protein kinases 1 and 2 (Mnk1 and 2), which 
influence translation initiation (Joshi et al., 2010). Mnk1 has been shown to 
prevent proteosomal degradation in response to growth factor stimulation in 
CHO-K1/COS1 cells (DaSilva et al., 2006). Posttranscriptional regulation of 
TNFα gene expression has been described in the presence of p38 inhibitor 
(Clark et al., 2003). Future experiments will show the underlying mechanism 
of the posttranscriptional regulation observed for MxA in human dermal 
fibroblasts. This study confirmed previous report that human dermal 
fibroblasts express IFNλR1 (Witte et al., 2009) and that IFNα can upregulate 
its expression. The ability of IFNα to enhance the expression levels of 
IFNλR1 is evidence for a cross-talk between type I and type III IFNs. A 
similar effect of IFNα on IFNλR1 has been reported in primary human 
hepatocytes (Duong et al., 2014).  
TGFβ1 is well known to induce collagen expression in fibroblasts. Types I 
and III collagens are the main ECM components, type IV collagen is the main 
component of the lamina densa in the basement membrane zone and Type 
VII collagen is a component of the anchoring fibrils lying beneath the lamina 
densa at the dermal-epidermal junction (Tiedtke, 2007). Results from this 
work shows that IFNλ1 potentiated the TGFβ-associated induction of 
collagen I, but not collagen type III, expression. IFNγ, a type II IFN has been 
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shown to have an inhibitory effect on TGFβ1-induced ECM or collagen 
deposition in primary human lung (Eickelberg et al., 2001) and in human 
foreskin fibroblasts through the blocking of Smad signalling (Ghosh et al., 
2001). Of interest, keloid derived dermal fibroblasts seem non-responsive to 
this IFNγ dependent type I collagen regulation (Hasegawa et al., 2003).  
Excessive secretion of type I collagen has been linked with disorganised fibre 
structure and hypertrophic scar formation, while a sufficient amount of type III 
collagen may prevent scar formation (Oliveira et al., 2009). The net effect of 
IFNλ1 on cutaneous repair and healing responses is not clear yet and needs 
to be further investigated. The ability of IFNλ1 to upregulate the expression of 
type IV (Col4A2) and VII collagens (Col7A1) suggests that it may support 
basement membrane integrity (Nystrom et al., 2013).  
The results of the proliferation experiments in human primary keratinocytes 
are consistent with the roles of IFNα and IFNλ1 as anti-proliferative agents. 
The results show that IFNλ1 does not have an inhibitory effect on dermal 
fibroblast proliferation and this may be due to its inability to induce STAT1 
phosphorylation in these cells. In addition, the anti-proliferative ability of 
GBP-1 on intestinal epithelial cells has been described (Capaldo et al., 2012) 
and in fibroblasts, no GBP-1 induction in the context of type III IFN 
stimulation was observed.  
This study has shown that IFNλR1 is active in human dermal fibroblasts 
through the activation of p38 and ERK pathways. It further shows that MxA 
induction by IFNλ1 occurs through a STAT1-independent pathway and this 
may also explain the role of this cytokine in enhancement of collagen 
expression and lack of anti-proliferative activity. Of note, IFNλ1 is highly 
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expressed in both the scarring and the non-scarring subtype of CLE. The 
data in this work suggest that IFNλ1 may not be a key molecule in the 
reduced proliferation seen in dermal fibroblasts from discoid CLE patients 
(Nyberg et al., 2000). Data are lacking so far describing the response of 
tissue cells to type I and III IFN in CLE disease subtypes. 
Egli et al have shown that in CMV treated foreskin derived fibroblast cell lines, 
IFNλ exerts an inhibitory action on IFNα induced antiviral activity (Egli et al., 
2014). However, IFNα also enhances fibroblasts susceptibility to IFNλ. It is 
thus possible that IFNλ, while important for the epidermal antiviral 
competence (Wolk et al., 2013), may exert important balancing and 
regulatory functions in the dermal compartment. One of the effects could be 
to counteract the type I IFN induced impairment of repair mechanisms. 
Despite the inhibitory effect of MAPK inhibitors seen in this work, it is 
important to note that off-target effects have also been reported, particularly 
for MEK1/2 inhibitors. Both U0126 and PD98059 have been shown to 
activate AMP-activated protein kinase; thus leading to increase in cellular 
AMP (Dokladda et al., 2005). Inhibition of calcium entry into the cell and 
reduction in mitochondrial respiration have been reported following the use of 
MEK1/2 inhibitors (Ripple et al., 2013; Wauson et al., 2013); these effects 
were not linked with inhibition of the MAPK pathway. Hence, interpretation of 
results following the use of these drugs should be done with some measure 
of caution and their use limited to short term studies. As an alternative to 
inhibition of the MAPK pathway using small molecule inhibitors, knocking 
down specific genes on the MAPK pathway using siRNA technology could be 
a better option. In addition, use of a positive control, such as a molecule or 
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protein that is well known to activate the MAPK pathway can help to monitor 
the effectiveness and specificity of the inhibitors. This will be examined by 
checking reduction/inhibition of MAPK phosphorylation and inhibition of 
expression of genes downstream ERK.  
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CHAPTER 6: DISCUSSION AND FUTURE WORK 
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6 Discussion  
The skin is a target organ of LE inflammation and CLE impacts negatively on 
the quality of life of patients (Klein et al., 2011). Scarring in visible areas of 
the body including irreversible hair loss is of great concern for affected 
patients. This work so far points to the importance of IFNλ and indeed IFNα 
in the pathogenesis of CLE. The abundance of these cytokines and 
associated ISGs may be very important in prognosis of scarring and non-
scarring subtypes of CLE. Nucleic acids (Poly I:C and polydA:dT) are 
important in the pathogenesis of CLE and the importance of TLR3 and RIG-I 
agonists has been shown in this work. TLR3 itself is very highly expressed in 
cutaneous lesion of patients with active LE (Zahn et al., 2010); however, the 
source of dsRNA in vivo is still unknown (Wittmann, 2011). Recent attention 
regarding IL-22 has focused on its  active role in normal wound healing (Lim 
and Savan, 2014). The double-edge nature of IL-22 (proinflammatory and 
repair promoting) may be very crucial in CLE and the ability to modulate the 
signalling pathways of this cytokine may determine its contribution to fibrosis; 
either to enhance inflammation, which is essential for development of 
scarring or to drive repair mechanism thereby reducing damaging effect of 
molecules, such as IFNs. As also highlighted in this work, the role of IL-22 in 
cell proliferation is still controversial. The effect of IL-22 on cell proliferation in 
vitro may be better evaluated by using fast growing cells, such as epithelial 
carcinoma cells. As observed in this work and that of others, IL-22 is involved 
in wound healing and cell migration (Ji et al., 2014). Scar formation is the 
hallmark of the outcome of chronic discoid lupus erythematosus (CDLE) and 
once the pathway has been initiated, it becomes impossible to stop the 
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eventual scarring outcome. The treatment options available, such as the use 
of antimalarial (chloroquine and hydroxylchloroquine) and methotrexate have 
failed to completely cure the disease and also prevent scar formation. 
Moreover, it has been reported that smoking negatively affects disease 
activity and significantly reduces the efficacy of hydroxylchloroquine and 
other antimalarials (Kuhn et al., 2014; Piette et al., 2012). Therefore, there is 
need to develop new therapy to combat this disease. With regards to scarring 
versus non-scarring outcomes, very early intervention may be necessary in 
order to halt the final scarring outcome. Results from this work could lead to 
the hypothesis that early administration or upregulation of IL-22 activity prior 
to full-onset CLE may be therapeutically beneficial. It would be interesting to 
understand why CLE keratinocytes have reduced expression of IL-22R1.   
It is now well known that IFNα plays important role in the pathogenesis of 
psoriasis (Lowes et al., 2014) and a possible role for IFNλ has been 
suggested (Wolk et al., 2013). Both IFNα and IFNλ are important molecules 
in the pathogenesis of CLE (Wenzel et al., 2010; Wittmann, 2011; Zahn et al., 
2011; Zahn et al., 2010). While psoriasis heals without permanent scar, 
CDLE heals with permanent scar. This study and the work of others have 
shown high expression of IL-22, IL-22R1 and SOCS3 in cutaneous lesion of 
patients with psoriasis (Sabat et al., 2014). By contrast, this study shows the 
absence/low expression of IL-22, low IL-22R1 expression in active lesions 
from CLE patients and reduced responsiveness of keratinocytes from CLE 
patients to IL-22. The absence of IL-22 expression in CDLE lesion has been 
reported elsewhere (Jabbari et al., 2014). These findings suggest that a 
balance in the type 1/type 17 activities in inflammatory skin diseases may be 
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essential in ensuring a scarless outcome. Although not produced by skin 
cells, IL-22 plays active roles in epidermal hyperproliferation, acanthosis, 
reduced apoptosis and epidermal thickening observed in psoriatic skin 
(Madonna et al., 2012; Sabat et al., 2014). On the other hand, increased 
apoptosis has been identified as one of the most important pathogenic 
factors in CLE (Kuhn and Bijl, 2008; Kuhn et al., 2006). IL-22 could be an 
important determining factor with regards to the eventual disease outcome in 
CLE and psoriasis. SOCS3 is induced by IFNα in human T cells and it is 
involved in the negative regulation of IFNα signalling as a form of feedback 
mechanism to control excessive stimulation of cells by IFNα (Bode et al., 
2003; Brender et al., 2001; Zimmerer et al., 2007). Damage to the bulge 
region (epidermal stem cell niche) of the hair follicle as a result of severe 
inflammation and presence of high number of CD8+ T lymphocytes has been 
reported in CDLE lesions (Al-Refu et al., 2009). Severe inflammation at the 
pilosebaceous gland and the length of inflammation were identified as 
important factors in acne scar. Inflammatory reaction was slower in patients 
with scar than in patients without scar (Fabbrocini et al., 2010; Holland et al., 
2004). Acne is a common disorder that results in atrophic scaring (ice pick 
scars) (Ghodsi et al., 2009). These reports show a strong link between 
severity and duration of inflammation and scar formation. Therefore, 
prevention or controlling early inflammation may offer a therapeutic “window” 
to treatment of scarring conditions.  
In a wider context of this study, early local administration of IL-22 or local 
upregulation of IL-22 activity by e.g. inhibiting IL-22BP, may help to reduce 
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pathogenic chemokines, such as CXCL9 and CXCL10 produced by skin 
resident cells; hence, reduction in tissues destruction.  
The dual role of IL-22 as both pro- and anti-inflammatory cytokine has been 
reported (Muhl et al., 2013; Sabat et al., 2014). The results presented here 
suggest a potential beneficial role of IL-22 in CLE; however, results are 
clearly very preliminary. Therefore, further and more extensive work has to 
be done in order to see if its use will be of any benefit to patients. This study 
also identifies the important immunological roles played by mesenchymal 
cells in the skin. The effects of IL-22 and IFNλ on dermal fibroblasts are only 
just emerging. The IL-10 family members can help maintain skin integrity and 
prevent excessive damage of the dermal compartment of the skin through 
their ability to enhance collagen expression and counteract the damaging 
effect of type I IFNs during viral infection and in pathogenesis of autoimmune 
diseases. 
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6.1 Future work 
Future work on the therapeutic potential or counter-regulatory role of IL-22 in 
inflammatory skin diseases will focus on the use of ex vivo or in vivo model of 
CLE. Despite the interesting finding on the counter-regulatory role of IL-22 on 
IFNλ-induced chemokines expression, it is important that more samples from 
different donors are used in order to fully confirm this finding. It would be 
interesting to be able to strongly upregulate IL-22R1 expression in CLE 
keratinocytes in order to increase responsiveness of these cells to IL-22. 
While this work has shown that human dermal fibroblasts can respond to 
IFNλ with subsequent downstream expression of MxA, it would be interesting 
to investigate the differences observed in mRNA and protein regulation in the 
presence of MAPK inhibitors. Due to the important roles played by both 
STAT1 and MxA in the pathogenesis of CLE, it would be important to see 
how dermal fibroblasts from CLE patients behave with regards to STAT1 and 
MAPKs activation and signalling. It is possible that these cells will respond 
differently to cells obtained from healthy individuals. STAT1 activation is 
really important in the anti-proliferative effect of IFNs (Maher et al., 2008). It 
would be interesting to see if these cells will respond to IFNλ with subsequent 
expression of more ISGs apart from MxA. This study has shown that CLE 
keratinocytes have reduced expression of IL-22R1 and it would thus be of 
high interest to see if fibroblasts from CLE patients express IL-22R1 and 
investigate if they are responsive to IL-22 with the evidence of a functional 
outcome.  
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